Document:

Exhibit
10.34 

 

SUBSCRIPTION
AGREEMENT

 

This
SUBSCRIPTION AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof
by and between Adhera Therapeutics, Inc. (f/k/a Marina Biotech, Inc.), a Delaware corporation (the “Company”),
and the undersigned investor in the Offering (as defined below) (the “Subscriber”).

 

WITNESSETH:

 

WHEREAS,
the Company is conducting a private offering (the “Offering”) consisting of up to an aggregate of $11,000,000
of shares of the Company’s Series F convertible preferred stock, par value $0.01 per share (the “Preferred Stock”),
at a purchase price equal to $5,000.00 per share (the “Purchase Price”), each share of Preferred Stock
being convertible into shares of the Company’s common stock, par value $0.006 per share (the “Common Stock”),
at a conversion price equal to $0.50, subject to adjustment;

 

WHEREAS,
in connection with a purchase of shares of Preferred Stock, each investor in the Offering will receive a five-year warrant (the
“Warrant”, and collectively with the Preferred Stock, the “Securities”) to
purchase such number of shares of Common Stock of the Company as is equal to 75% of the number of shares of Common Stock issuable
upon conversion of the shares of Preferred Stock issued to such investor at an exercise price equal to $0.55 per share, subject
to adjustment thereunder;

 

WHEREAS,
the Company has engaged Maxim Merchant Capital, a division of Maxim Group LLC (Member FINRA/SIPC) to act as the sole placement
agent for the Offering (the “Placement Agent”);

 

WHEREAS,
the aggregate gross proceeds from the Offering shall be up to a maximum offering amount of $11,000,000 (the “Maximum
Offering Amount”);

 

WHEREAS,
the Offering is being made through the Placement Agent on a “commercially reasonable best efforts” basis
to a limited number of “accredited investors” (as that term is defined by Rule 501(a) of Regulation
D (“Regulation D”) promulgated under the Securities Act of 1933, as amended (the “Securities
Act”), by the Securities and Exchange Commission (the “SEC’) to attain the Maximum Offering
Amount;

 

WHEREAS,
the Subscriber desires to purchase such number of shares of Preferred Stock (together with the associated Warrants) as set forth
on the signature page hereof;

 

WHEREAS
the Subscriber’s subscription for Securities will be made in accordance with and subject to the terms and conditions of
this Agreement and the Company’s Confidential Private Placement Memorandum dated June 7, 2018, together with all amendments
thereof and supplements and exhibits thereto, including the documents incorporated by reference therein, and as any of the foregoing
may be amended from time to time (the “Memorandum”); and

 

WHEREAS,
the Company and the Subscriber are executing and delivering this Agreement, and performing the transactions contemplated hereby
including the sale and purchase of the Securities, in reliance upon the exemption from the registration requirements of the Securities
Act afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.

 

    	1

     

    

 

NOW,
THEREFORE, in consideration of the premises and the mutual representations and covenants hereinafter set forth, the parties hereto
do hereby agree as follows:

 

I.
SUBSCRIPTION FOR
SHARES AND REPRESENTATIONS BY SUBSCRIBER

 

1.1
Subject to the terms and conditions hereinafter set forth (including Section 1.19 hereof) and as set forth in the Memorandum,
the Subscriber hereby subscribes for and agrees to purchase from the Company, and the Company agrees to sell to the Subscriber,
such number of shares of Preferred Stock as is set forth on the signature page hereof (and a corresponding number of Warrants).
The aggregate Purchase Price is payable by wire transfer, to be held in escrow until the applicable Closing (as defined below),
to Collegiate Peaks Bank, in its capacity as the escrow agent for the Offering (the “Escrow Agent”),
as follows:

 

	 	Bank:	 	Collegiate
    Peaks Bank
	 	ABA
    Number:	 	102105997
	 	Account
    #:	 	0410037903
	 	Account
    Name:	 	Corporate
    Stock Transfer as Escrow Manager for Marina 

Biotech, Inc.

 

1.2
The Subscriber understands, acknowledges and
agrees that, except as otherwise set forth in Section 3.2 or otherwise required by law, once irrevocable, (i) the Subscriber is
not entitled to cancel, terminate or revoke his, her or its subscription pursuant to this Agreement or any other obligations of
the Subscriber hereunder and (ii) this Agreement and the Subscriber’s obligations hereunder shall survive the death or disability
of the Subscriber and shall be binding upon and inure to the benefit of each of the parties and their respective heirs, executors,
administrators, successors, legal representatives and permitted assigns. If the Subscriber is more than one person, the obligations
of the Subscriber hereunder shall be joint and several and the agreements, representations, warranties and acknowledgments of
the Subscriber in this Agreement shall be deemed to be made by and be binding upon each such person and his, her, its or their
heirs, executors, administrators, successors, legal representatives and permitted assigns.

 

1.3
The Subscriber recognizes that the purchase of
the Securities involves a high degree of risk including, but not limited to, the following: (a) the Company requires substantial
funds in addition to the proceeds of the Offering in order to fund its operations and the development and commercialization of
its product candidates; (b) an investment in the Company is highly speculative, and only investors who can afford the loss of
their entire investment should consider investing in the Company and the Securities; (c) the Subscriber may not be able to liquidate
the Subscriber’s investment in the Securities; (d) transferability of the Securities including, if and when issued, the
shares of Common Stock issuable upon conversion of the Preferred Stock (the “Conversion Shares”) and/or
exercise of the Warrants (the “Warrant Shares” and collectively with the Conversion Shares, the “Underlying
Shares”) may be extremely limited or restricted by applicable law; (e) in the event of a future disposition of the
Securities (or any securities issuable upon conversion and/or exercise of the Securities), the Subscriber could sustain the loss
of the Subscriber’s entire investment; (f) the Company has not paid any dividends since its inception, does not anticipate
paying any dividends in the near future and any future dividends will be subject to the discretion of and approval by the Company’s
board of directors; and (g) each of the other risks set forth in or incorporated by reference into the “Risk Factors”
section of the Memorandum, which are incorporated herein by reference.

 

    	2

     

    

 

1.4
At the time such Subscriber was offered the Securities,
the Subscriber was, and as of the date hereof is, and on the date on which it exercises any Warrants or converts any shares of
Preferred Stock, it will be, an “accredited investor” as defined in Rule 501(a) promulgated under the Securities Act.
The Subscriber hereby represents and warrants to the Company that the Subscriber’s responses to the investor questionnaire
substantially in the form attached as Exhibit A to this Agreement (the “Purchaser Questionnaire”)
are true, correct and complete in all respects.

 

1.5
The Subscriber hereby acknowledges, represents
and warrants that: (a) the Subscriber has adequate means of providing for the Subscriber’s current financial needs and contingencies;
(b) the Subscriber has knowledge and experience in business and financial matters, prior investment experience (including investment
in securities that are non-listed, unregistered and/or not traded on a national securities exchange), or employed the services
of a “purchaser representative” (as defined in Rule 501 of Regulation D), attorney and/or accountant to read and review
all of the documents furnished or made available by the Company to the Subscriber, to evaluate the merits and risks of an investment
in the Securities on the Subscriber’s behalf; (c) the Subscriber is able to bear the economic risk that the Subscriber assumes
by investing in the Securities; and (d) the Subscriber can afford a complete loss of the Subscriber’s investment in the
Securities.

 

1.6
The Subscriber hereby (i) acknowledges receipt
and careful review of this Agreement, the Memorandum, the certificate of designations substantially in the form attached hereto
as Exhibit B to be filed with the Secretary of State of the State of Delaware for the Preferred Stock (the “Certificate
of Designation”), the form of Warrant attached hereto as Exhibit C, and all other exhibits, annexes and appendices
thereto, which are incorporated herein by reference (collectively, the “Offering Materials”), and has
had access to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (collectively with the
exhibits thereto and as amended, the “Form 10-K”), the Company’s Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 2018 (collectively with the exhibits thereto and as amended, the “Form 10-Q”)
and the other periodic, current and other reports filed or furnished by the Company pursuant to the Securities Act and the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Sections 13(a) or 15(d)
thereof, as publicly filed and available on the website of the SEC (such materials, collectively, the “SEC Reports”);
(ii) represents that the Subscriber has been furnished by the Company with all information regarding the Company, the terms and
conditions of the Offering and any additional information that the Subscriber has requested or desired to know, and has been afforded
the opportunity to ask questions of and receive answers from duly authorized officers or other representatives of the Company
concerning the Company and the terms and conditions of the Offering; provided, however, that no investigation performed by or
on behalf of the Subscriber shall limit or otherwise affect its right to rely on the representations and warranties of the Company
expressly contained herein; and (c) acknowledges that the projections and other “forward-looking statements” (within
the meaning of U.S. securities laws) of the Company that are contained in the Offering Materials should not be relied upon in
making the decision to invest in the Securities, that such projections are subject to change and that there is no assurance that
such projections will be met.

 

    	3

     

    

 

1.7
(a) In making the decision to invest in the Securities,
the Subscriber has relied solely upon the information provided by the Company in this Agreement and the Memorandum. To the extent
necessary, the Subscriber has retained, at its own expense, and relied upon appropriate professional advice regarding the investment,
tax and legal merits and consequences of this Agreement and the purchase of the Securities hereunder. The Subscriber disclaims
reliance on any statements made or information provided by any person or entity in the course of Subscriber’s consideration
of an investment in the Securities other than this Agreement and the Memorandum and the results of Subscriber’s own independent
investigation.

 

(b)
The Subscriber represents that (i) the Subscriber
was contacted regarding the sale of the Securities by the Company or the Placement Agent (or another person whom the Subscriber
believed to be an authorized agent or representative thereof with whom the Subscriber had a prior substantial pre-existing relationship),
(ii) the Subscriber did not learn of the Offering by means of any form of general solicitation or general advertising, (iii) the
Subscriber did not receive or review any advertisement, article, notice or other communication published in a newspaper or magazine
or similar media or broadcast over television or radio, whether closed circuit, or generally available, with respect to the Offering
and (iv) the Subscriber did not attend any seminar meeting or industry investor conference whose attendees were invited by any
general solicitation or general advertising with respect to the Offering.

 

1.8
The Subscriber hereby acknowledges that the Offering
has not been reviewed by the SEC or any state regulatory authority and that the Offering is intended to be exempt from the registration
requirements of Section 5 of the Securities Act pursuant to the exemption therefrom provided by Section 4(a)(2) of the Securities
Act and Rule 506 of Regulation D promulgated thereunder. The Subscriber understands that the Securities (including any Underlying
Shares issuable upon the conversion and/or exercise of the Securities) have not been and will not be registered under the Securities
Act or under any state securities or “blue sky” laws and agrees not to sell, pledge, assign or otherwise transfer
or dispose of the Securities and any Underlying Shares unless and until they are registered under the Securities Act and under
any applicable state securities or “blue sky” laws or pursuant to an available exemption therefrom. The Subscriber
hereby represents that the Subscriber is purchasing the Securities for the Subscriber’s own account for investment purposes
and not with a view toward the resale or distribution to others; provided, however, that nothing contained herein shall constitute
an agreement by the Subscriber to hold the Securities for any particular length of time and the Company acknowledges that the
Subscriber shall at all times retain the right to dispose of the Securities as it may determine in its sole discretion, subject
to any restrictions imposed by applicable law. The Subscriber, if an entity, further represents that it was not formed for the
purpose of purchasing the Securities.

 

    	4

     

    

 

1.9
The Subscriber consents to the placement of a
legend on any certificate or other document evidencing the Securities and, if and when issued, the Underlying Shares, that such
securities have not been registered under the Securities Act or any state securities or “blue sky” laws and
setting forth or referring to the restrictions on transferability and sale thereof contained in this Agreement. The Subscriber
is aware that the Company will make a notation in its appropriate records with respect to the restrictions on the transferability
of such Securities. The legend to be placed on each certificate shall be in form substantially similar to the following:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”)
OR ANY STATE SECURITIES OR “BLUE SKY LAWS,” AND MAY BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED
ONLY PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN
A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS.”

 

1.10
The Subscriber hereby represents that the address
of the Subscriber set forth on the signature page hereto is the Subscriber’s principal residence if the Subscriber is an
individual or its principal business address if the Subscriber is an entity.

 

1.11
The Subscriber represents that the Subscriber
has full power and authority (corporate, statutory and otherwise) or capacity, as applicable, to execute and deliver this Agreement
and to purchase the Securities. This Agreement constitutes the legal, valid and binding obligation of the Subscriber, enforceable
against the Subscriber in accordance with its terms.

 

1.12
If the Subscriber is a corporation, partnership,
limited liability company, trust, employee benefit plan, individual retirement account, Keogh Plan, or other tax-exempt entity,
it is authorized and qualified to invest in the Company and the person signing this Agreement on behalf of such entity has been
duly authorized by such entity to do so.

 

1.13
The Subscriber acknowledges that if the Subscriber
is a Registered Representative of a Financial Industry Regulatory Authority (“FINRA”) member firm, the
Subscriber must give such firm the notice required by the FINRA’s Rules of Fair Practice, receipt of which must be acknowledged
by such firm in the Subscriber’s Purchaser Questionnaire.

 

1.14
To effectuate the terms and provisions of this
Agreement, the Subscriber hereby appoints the Placement Agent as its attorney-in-fact (and the Placement Agent hereby accepts
such appointment) for the purpose of carrying out the provisions of the Escrow Agreement by and between the Company, the Placement
Agent and the Escrow Agent (the “Escrow Agreement”) including, without limitation, taking any action
on behalf of, or at the instruction of, the Subscriber and executing any release notices required under the Escrow Agreement and
taking any action and executing any instrument that the Placement Agent may deem necessary or advisable (and lawful) to accomplish
the purposes hereof or thereof. All acts done under the foregoing authorization are hereby ratified and approved and neither the
Placement Agent nor any designee nor agent thereof shall be liable for any acts of commission or omission, for any error of judgment,
for any mistake of fact or law except for acts of gross negligence or willful misconduct. This power of attorney, being coupled
with an interest, is irrevocable while the Escrow Agreement remains in effect.

 

    	5

     

    

 

1.15
The Subscriber agrees not to issue any public
statement with respect to the Offering, Subscriber’s investment or proposed investment in the Company or the terms of this
Agreement or any other agreement or covenant between them and the Company without the Company’s prior written consent, except
such disclosures as may be required under applicable law.

 

1.16
The Subscriber understands, acknowledges and
agrees with the Company that this subscription may be rejected, in whole or in part, by the Company, in the sole and absolute
discretion of the Company, at any time before the applicable Closing (as defined below) notwithstanding prior receipt by the Subscriber
of notice of acceptance by the Company of the Subscriber’s subscription.

 

1.17
The Subscriber acknowledges and agrees that (i)
the information contained in the Offering Materials or otherwise made available to the Subscriber by the Company in connection
with the Offering is confidential and non-public and (ii) all such information shall be kept in confidence by the Subscriber and
neither used by the Subscriber for the Subscriber’s personal benefit (other than in connection with this Agreement) nor
disclosed to any third party for any reason, notwithstanding that a Subscriber’s subscription may not be accepted by the
Company; provided, however, that (a) the Subscriber may disclose such information to its affiliates and advisors who may have
a need for such information in connection with providing advice to the Subscriber with respect to its investment in the Company
so long as such affiliates and advisors have an obligation of confidentiality to the Subscriber no less restrictive than the restrictions
contained in this Section 1.17, and (b) this obligation shall not apply to any such information that (i) is part of the public
knowledge or literature and readily accessible at the date hereof, (ii) becomes part of the public knowledge or literature and
readily accessible by publication (except as a result of a breach of this provision) after the date hereof or (iii) is received
from a third party that is not under any obligation of confidentiality with respect to such information.

 

1.18
Subscriber understands that the Securities are
being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and
state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Subscriber’s compliance
with, the representations, warranties, agreements, acknowledgements and understandings of such Subscriber set forth herein in
order to determine the availability of such exemptions and the eligibility of such Subscriber to acquire the Securities. The Subscriber
agrees to supply the Company, within five (5) days after the Subscriber receives the request therefor from the Company, with such
additional information concerning the Subscriber as the Company deems necessary or advisable for purposes of making such determination.

 

1.19
The Subscriber understands that Rule 144 promulgated
under the Securities Act (“Rule 144”) requires, among other conditions, a minimum holding period of
six-months prior to the resale of securities acquired in a non-public offering without having to satisfy the registration requirements
under the Securities Act. The Subscriber understands and hereby acknowledges that the Company is under no obligation to register
the Securities under the Securities Act or any state securities or “blue sky” laws or to assist the Subscriber in
obtaining an exemption from any such registration requirements.

 

1.20
The Subscriber agrees to hold the Company and
its directors, officers, employees, controlling persons and agents (including the Company’s legal counsel and the Placement
Agent and its managers, members, officers, directors, employees, counsel, controlling persons and agents) and their respective
heirs, representatives, successors and assigns harmless from and to indemnify them against all liabilities, costs and expenses
incurred by them as a result of (i) any misrepresentation made by the Subscriber contained in this Agreement (including Article
VII) or breach of any warranty by the Subscriber contained in this Agreement or in any exhibits attached hereto; (ii) any untrue
statement of a material fact made by the Subscriber contained herein; or (iii) after any applicable notice and/or cure periods,
any breach or default in performance by the Subscriber of any covenant or undertaking to be performed by the Subscriber hereunder,
or pursuant to any other Offering Materials entered into by the Company and Subscriber relating hereto. Notwithstanding the foregoing,
in no event shall the liability of the Subscriber hereunder be greater than the aggregate Purchase Price paid for the Securities
by the Subscriber as set forth on the signature page hereto.

 

    	6

     

    

 

1.21
The Subscriber is an entity, upon request of
the Company, the Subscriber will provide true, complete and current copies of all relevant documents creating the Subscriber,
authorizing its investment in the Company and/or evidencing the due authority of the signatory to this Agreement.

 

II.
REPRESENTATIONS
BY AND COVENANTS OF THE COMPANY

 

The
Company hereby represents and warrants to the Subscriber, as of the date of this Agreement (other than representations and warranties
that relate to a specific date, which are given as of such date) and except as set forth in the Memorandum or in the SEC Reports,
as follows:

 

2.1
Organization, Good Standing and Qualification.
The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and
has full corporate power and authority to own and use its properties and assets as currently owned and conduct its business as
currently conducted. Except as set forth on Schedule 2.1 attached hereto, each of the Company’s wholly-owned subsidiaries
(the “Subsidiaries”) is an entity duly organized, validly existing and in good standing under the laws
of the jurisdiction of its incorporation with the requisite power and authority to own and use its properties and assets and to
conduct its business as currently conducted. Neither the Company, nor any of its Subsidiaries is in violation of any of the provisions
of their respective articles of incorporation, by-laws or equivalent organizational or charter documents, including, but not limited
to the Company’s Certificate of Incorporation, as amended (the “COI”), or the Company’s
Bylaws, as amended (the “Bylaws,” and collectively with the COI, the “Charter Documents”).
Each of the Company and its Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation
in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, would not have a material adverse effect
on (i) the legal and valid issuance of the Securities, (ii) the enforceability of this Agreement against the Company or the Company’s
ability to perform, its obligations hereunder, or (iii) the results of operations, assets, business and financial condition of
the Company and its Subsidiaries, taken as a whole (any of (i), (ii) or (iii), a “Material Adverse Effect”).

 

    	7

     

    

 

2.2
Capitalization and Voting Rights. As of
the date of this Agreement, the Company was authorized to issue 180,000,000 shares of Common Stock, of which 10,761,684 shares
were issued and outstanding, and 100,000 shares of preferred stock were authorized, of which 90,000 have been designated as Series
A Junior Participating Preferred Stock (of which none are issued and outstanding), 1,000 have been designated as Series B Preferred
Stock (none of which are outstanding), 1,200 have been designated as Series C Convertible Preferred Stock (of which 100 are issued
and outstanding), 220 have been designated as Series D Convertible Preferred Stock (of which 40 are issued and outstanding), 3,500
have been designated as Series E Convertible Preferred Stock (of which 3,490.28 are issued and outstanding), and 2,200 have been
designated as Series F Convertible Preferred Stock (of which 308 are issued and outstanding). As of the date hereof: (i) there
are no outstanding securities of the Company or any of its Subsidiaries which contain any preemptive, redemption or similar provisions;
(ii) no holder of securities of the Company or any Subsidiary is entitled to preemptive or similar rights arising out of any agreement
or understanding with the Company or any Subsidiary by virtue of the Offering; (iii) there are no contracts, commitments, understandings
or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or
any of its Subsidiaries; (iv) neither the Company nor any Subsidiary has any outstanding stock appreciation rights, “phantom
stock” plans or any similar plan or agreement; and (v) except as set forth on Schedule 2.2, there are no outstanding options,
warrants, agreements, convertible securities, preemptive rights or other rights to subscribe for or to purchase or acquire, any
shares of capital stock of the Company or any Subsidiary or contracts, commitments, understandings, or arrangements by which the
Company or any Subsidiary is or may become bound to issue any shares of capital stock of the Company or any Subsidiary, or securities
or rights convertible or exchangeable into shares of capital stock of the Company or any Subsidiary. Other than restrictions imposed
by applicable law, there are no restrictions upon the voting or transfer of any of the shares of capital stock of the Company
pursuant to the Charter Documents or any material agreement or other instrument to which the Company is a party or by which the
Company is bound. All of the issued and outstanding shares of capital stock of the Company are validly issued, fully paid and
nonassessable and the shares of capital stock of the Subsidiaries are owned by the Company, free and clear of any mortgages, pledges,
liens, claims, charges, encumbrances or other restrictions (collectively, “Encumbrances”). All of the
Company’s outstanding capital stock has been issued in accordance with the applicable provisions of the Securities Act and
any other applicable securities laws. Except as set forth on Schedule 2.2, the issuance and sale of the Securities, as
contemplated hereby, will not obligate the Company to issue shares of Common Stock or other securities to any other person (other
than other investors in the Offering) and will not result in the adjustment of the exercise, conversion, exchange or reset price
of any outstanding Company security. The Company does not have outstanding stockholder purchase rights or “poison pill”
or (any arrangement granting substantially similar rights) in effect giving any person the right to purchase any equity interest
in the Company upon the occurrence of the transactions contemplated hereby.

 

2.3
Authorization; Enforceability. The Company
has all corporate right, power and authority to enter into, execute and deliver this Agreement and each other agreement, document,
instrument and certificate to be executed by the Company in connection with the consummation of the transactions contemplated
hereby, and to perform fully its obligations hereunder and thereunder. All corporate action on the part of the Company, its directors
and stockholders necessary for the (a) authorization execution, delivery and performance of this Agreement by the Company; and
(b) authorization, sale, issuance and delivery of the Securities and, if and when issued, the Underlying Shares, has been taken.
This Agreement has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms, subject to laws of general application relating to bankruptcy,
insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies,
and to limitations of public policy. The Securities are duly authorized and, when issued and paid for in accordance with the terms
of this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Encumbrances other than
restrictions on transfer provided for in the Offering Materials. The Underlying Shares, when issued in accordance with the terms
of the applicable Offering Materials, will be validly issued, fully paid and nonassessable, free and clear of all Encumbrances
imposed by the Company other than restrictions on transfer provided for in the Offering Materials. The Company has reserved a
sufficient number of shares of Common Stock for issuance upon the conversion of the Preferred Stock and the exercise of the Warrants.

 

    	8

     

    

 

2.4
No Conflict; Governmental Consents.

 

(a)
The execution and delivery by the Company of
this Agreement, the issuance and sale of the Securities (including, if and when issued, the Underlying Shares) and the consummation
of the other transactions contemplated hereby do not and will not (i) result in the violation of any law, statute, rule, regulation,
order, writ, injunction, judgment or decree of any court or governmental authority to or by which the Company is bound including
without limitation all foreign, federal, state and local laws applicable to the Company, except in each case as would not have
a Material Adverse Effect, (ii) conflict with or violate any provision of the Charter Documents, and (iii) conflict with, or result
in a material breach or violation of, any of the terms or provisions of, or constitute (with or without due notice or lapse of
time or both) a default or give to others any rights of termination, amendment, acceleration or cancellation (with or without
due notice, lapse of time or both) under any Material Contract (as defined below) to which the Company or any Subsidiary is a
party or by which any of them is bound, nor result in the creation or imposition of any Encumbrances upon any of the properties
or assets of the Company or any Subsidiary.

 

(b)
Except as set forth on Schedule 2.4(b),
no approval by the holders of Common Stock, or other equity securities of the Company, is required to be obtained by the Company
in connection with the authorization, execution, delivery and performance of this Agreement or in connection with the authorization,
issue and sale of the Securities and, upon issuance, the Underlying Shares, except as has been previously obtained.

 

(c)
No consent, approval, authorization or other
order of any governmental authority or any other person is required to be obtained by the Company in connection with the authorization,
execution, delivery and performance of this Agreement or in connection with the authorization, issue and sale of the Securities
and, upon issuance, the Underlying Shares, except such post-sale filings as may be required to be made with the SEC, FINRA, the
OTC Markets and with any state or foreign blue sky or securities regulatory authority, all of which shall be made when required.

 

    	9

     

    

 

2.5
SEC Reports; Financial Statements. The
Company has filed all SEC Reports required to be filed by it under the Securities Act and the Exchange Act since January 1, 2017
(the “Reference Date”) (or such shorter period as the Company was required by law to file such reports)
(the “Adhera SEC Reports”) on a timely basis, or timely filed a valid extension of such time of filing
and has filed the Adhera SEC Reports prior to the expiration of any such extension. As of their respective dates, the Adhera SEC
Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations
of the SEC promulgated thereunder, and none of the Adhera SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the
Adhera SEC Reports (the “Adhera Financial Statements”) comply in all material respects with applicable
accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing. The
Adhera Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a consistent
basis during the periods involved, except as may be otherwise specified in such financial statements or the footnotes thereto,
and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and
for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments.

 

2.6
Regulatory Permits: Licenses. The Company
and the Subsidiaries possess all certificates, authorizations, licenses and permits issued by the appropriate federal, state,
local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports and the
Memorandum (“Material Permits”), except where the failure to possess such Material Permits would not
have a Material Adverse Effect, and neither the Company nor any Subsidiary has received any notice of any action, arbitration,
claim, hearing, litigation or suit (whether civil, criminal, administrative, judicial or investigative, whether formal or informal,
whether public or private) commenced, brought, conducted or heard by or before any federal, state, local or foreign government
or any court of competent jurisdiction, administrative or regulatory body, agency, bureau, or commission in any domestic or foreign
jurisdiction, any appropriate division of any of the foregoing or any arbitrator, or other legal action (each, a “Proceeding”)
relating to the revocation or modification of any Material Permit.

 

2.7
Litigation. Except as set forth on Schedule
2.7, there are no pending or, to the Company’s knowledge, threatened Proceedings against the Company or any Subsidiary which
would have a Material Adverse Effect. Neither the Company nor any Subsidiary is a party or subject to the provisions of any order,
writ, injunction, judgment or decree of any court or government agency or instrumentality which would materially adversely affect
the business, property, financial condition or operations of the Company and its Subsidiaries taken as a whole. There is no Proceeding
by the Company or any Subsidiary currently pending in any court or before any arbitrator or that the Company or any Subsidiary
intends to initiate. None of the Company, any Subsidiary or any director or officer thereof is, or since the date of the filing
of the Form 10-K has been, the subject of any action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There is no pending or, to the Company’s knowledge, contemplated investigation
by the SEC involving the Company or any current director or officer of the Company.

 

    	10

     

    

 

2.8
Investment Company. The Company is not
an “investment company” within the meaning of such term under the Investment Company Act of 1940, as amended, and
the rules and regulations of the SEC promulgated thereunder.

 

2.9
Brokers. Except for the Placement Agent,
neither the Company nor any of the Company’s officers, directors or employees has employed or engaged any broker or finder
in connection with the transactions contemplated by this Agreement and no fee or other compensation is or will be due and owing
on behalf of the Company to any broker, finder, underwriter, placement agent or similar person in connection with the transactions
contemplated by this Agreement.

 

2.10
Intellectual Property; Employees.

 

(a)
The Company owns or possesses all material legal
rights to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary
rights and processes necessary for its business as presently conducted (collectively, the “Intellectual Property Rights”)
as set forth on Schedule 2.10. There are no material outstanding options, licenses or agreements of any kind relating to
the Company’s Intellectual Property Rights, other than as set forth in the Memorandum, nor is the Company bound by or a
party to any material options, licenses or agreements of any kind with respect to the Intellectual Property Rights of any other
person or entity other than such licenses or agreements arising from the purchase of “off the shelf” or standard products.
Since the Reference Date, the Company has not received any written communications alleging that the Company has violated or, by
conducting its business as presently conducted, would violate any Intellectual Property Rights of any other person or entity.
The Company and its Subsidiaries have taken reasonable measures to protect the secrecy, confidentiality and value of all of their
Intellectual Property Rights, except where failure to do so would not, individually or in the aggregate, have a Material Adverse
Effect

 

(b)
The Company is not aware of any obligation on
the part of any Company Employee under any contract (including licenses, covenants or commitments of any nature), other agreement
or judgment, decree or order of any court or administrative agency, that would materially adversely interfere with such employee’s
duties to the Company or that would conflict with the Company’s business as presently conducted.

 

(c)
To the Company’s knowledge, (i) no employee
of the Company, or any consultant with whom the Company has contracted, is in violation of any term of any employment contract,
proprietary information agreement or any other agreement relating to the right of any such individual to be employed by, or to
contract with, the Company and (ii) the continued employment by the Company of its employees, and the performance of the Company’s
contracts with its independent contractors, will not result in any such violation. Since the Reference Date, the Company has not
received any written notice alleging that any such violation has occurred. No employee of the Company has been granted the right
to continued employment by the Company or to any compensation following termination of employment with the Company except as would
not have a Material Adverse Effect. To the Company’s knowledge, no officer or key employee intends to terminate his, her
or their employment with the Company, nor does the Company have a present intention to terminate any such employee.

 

    	11

     

    

 

2.11
Title to Properties and Assets; Liens, Etc.
The Company has good and marketable title to its properties and assets and good title to its leasehold estates, including its
Intellectual Property Rights, which are, to the Company’s knowledge, valid and enforceable, with all maintenance or other
required fees having been paid.

 

2.12
Obligations to Related Parties. There
are no obligations of the Company to officers, directors, stockholders, or employees of the Company other than (a) for payment
of salary or other compensation for services rendered, (b) reimbursement for reasonable expenses incurred on behalf of the Company
and (c) for other standard employee benefits made generally available to all employees (including stock option agreements under
the Company’s equity plans). None of the officers or directors of the Company and, to the Company’s knowledge, none
of the employees of the Company, is presently a party to any transaction with the Company or any Subsidiary (other than as holders
of Company securities and for services as employees, officers and directors) required to be disclosed under applicable SEC rules
and regulations.

 

2.13
Material Changes. Since the Reference
Date, (i) there has been no event, occurrence or development that has had a Material Adverse Effect, (ii) the Company has not
incurred any material liabilities (contingent or otherwise) other than (A) trade payables, accrued expenses and other liabilities
incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in
the Company’s financial statements pursuant to generally accepted accounting principles or required to be disclosed in filings
made with the SEC, (iii) the Company has not altered its method of accounting or the identity of its auditors, (iv) the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or
made any agreements to purchase or redeem any shares of its capital stock, and (v) the Company has not issued any equity securities
to any officer, director or affiliate, except pursuant to existing Company stock compensation plans. The Company does not have
pending before the SEC any request for confidential treatment of information.

 

2.14
Compliance. The Company is in material
compliance with all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated
thereunder.

 

2.15
No General Solicitation. Assuming the
accuracy of the Placement Agent’s representations in the placement agency agreement to be entered into by the Company and
the Placement Agent, none of the Company, its Subsidiaries, any of its or their affiliates, or any person acting on its or their
behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection
with the Offering.

 

2.16
Private Placement; No Integrated Offering.
Assuming the accuracy of the Subscriber’s representations and warranties set forth in this Agreement, no registration under
the Securities Act is required for the offer or sale of the Securities by the Company as contemplated hereby. Assuming the accuracy
of the Placement Agent’s representations in the placement agency agreement to be entered into by the Company and the Placement
Agent, none of the Company, its Subsidiaries, any of its or their affiliates, or any person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any security, solicited any offers to buy any security or taken any other
action, which, under the circumstances would require such registration or cause this Offering to be integrated with prior offerings
by the Company for purposes of the Securities Act or the rules of the OTC Markets.

 

    	12

     

    

 

2.17
Application of Takeover Protections. The
Company has taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination,
poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Charter Documents
or the laws of the State of Delaware that otherwise would be applicable as a result of the Subscriber and the Company fulfilling
their obligations or exercising their rights under this Agreement, including, without limitation, the Company’s issuance
of the Securities and the Subscriber’ ownership of the Securities.

 

2.18
Taxes. Since the Reference Date (i) the
Company and each of its Subsidiaries has filed all U.S. federal, state, local and foreign tax returns which are required to be
filed by each of them and all such returns are true and correct in all material respects, except for such failures to file which
would not have a Material Adverse Effect, (ii) the Company and each of its Subsidiaries has paid all taxes required to be paid
pursuant to such returns or pursuant to any assessments received by any of them, and have withheld any amounts which any of them
are obligated to withhold from amounts owing to any employee, creditor or third party and (iii) the Company and each of its Subsidiaries
has properly accrued all taxes required to be accrued and/or paid pursuant to applicable law, except where the failure to accrue
would not have a Material Adverse Effect. To the knowledge of the Company, the tax returns of the Company and its Subsidiaries
are not currently being audited by any state, local or federal authorities. Neither the Company nor any of its Subsidiaries has
waived any statute of limitations with respect to taxes or agreed to any extension of time with respect to any tax assessment
or deficiency.

 

2.19
Registration Rights. Except as set forth
on Schedule 2.19, no person has any right to cause the Company to effect the registration under the Securities Act of any securities
of the Company.

 

2.20
Listing and Maintenance Requirements.
The Common Stock is registered pursuant to Section 12(g) of the Exchange Act, and the Company has taken no action designed to,
or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange
Act nor has the Company received any notification that the SEC is contemplating terminating such registration. The Company has
not, since the Reference Date, received notice from any trading market on which the Common Stock is or has been listed or quoted
to the effect that the Company is not in compliance with the listing or maintenance requirements of such trading market. The Company
is in material compliance with the continued listing requirements of the OTCQB tier of the OTC Markets.

 

2.21
Material Contracts. The SEC Reports contain
all material contracts, agreements, commitments, arrangements, leases, policies or other instruments to which either the Company
or any of its Subsidiaries is a party or by which any of them is bound, which are required to be filed pursuant to the Securities
Act or the Exchange Act (the “Material Contracts”). The Material Contracts are valid and in full force
and effect, enforceable against the Company and any of the Subsidiaries party thereto and, to the Company’s knowledge, against
the other parties thereto. Neither the Company nor any Subsidiary is in violation of, or default under (and there does not exist
any event or condition which, after notice or lapse of time or both, would constitute such a default under), any Material Contract.
To the Company’s knowledge, none of the other parties to any Material Contract are in violation of or default under any
Material Contract in any material respect. Neither the Company nor any Subsidiary has received any notice of cancellation or any
written communication threatening cancellation of any Material Contract which is currently in effect by any other party thereto.

 

    	13

     

    

 

2.22
U.S. Food and Drug Administration. As
to each product candidate subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that
is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each
such product, a “Product Candidate”), such Product Candidate is being manufactured, packaged, labeled,
tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar
laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval,
good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising,
record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There
is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal
or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries,
and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA
or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses
of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal
of advertising or sales promotional materials relating to, any Product, (iii) imposes a clinical hold on any clinical investigation
by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries,
(v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or
(vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either
individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company
have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the
FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United
States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to
approving or clearing for marketing any product being developed or proposed to be developed by the Company. Statements in the
SEC Reports concerning the Company’s applications, filings, submissions and proceedings with the FDA under the FDCA fairly
summarize in all material respects such matters.

 

2.23
Contributions. Neither the Company nor
any Subsidiary has directly or indirectly, (i) made any unlawful contribution to any candidate for public office, or failed to
disclose fully where required by law any contribution in violation of law, or (ii) made any payment to any federal or state governmental
officer or official, or other person charged with similar public or quasi-public duties, other than payments required or permitted
by the laws of the United States or any jurisdiction thereof.

 

    	14

     

    

 

2.24
Disclosure. Except with respect to the
material terms and conditions of the transactions contemplated by the Offering Materials, the Company confirms that neither it
nor any other person acting on its behalf has provided the Subscriber or its agents or counsel with any information that it believes
constitutes or might constitute material, non-public information. The Company understands and confirms that the Subscriber will
rely on the foregoing representation in effecting transactions in securities of the Company.

 

2.25
Office of Foreign Assets Control. Neither
the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, employee or affiliate of the Company
or any Subsidiary, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S.
Treasury Department (“OFAC’).

 

2.26
No Disqualification Events. With respect
to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any
of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the
offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated
on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the
Company in any capacity at the time of sale (each, an “Issuer Covered Person” and, together, “Issuer
Covered Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i)
to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification Event
covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person
is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under
Rule 506(e), and has furnished to the Subscribers a copy of any disclosures provided thereunder.

 

2.27
Other Covered Persons. Other than the
Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly
or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.

 

III.
TERMS OF SUBSCRIPTION

 

3.1
The Securities will be offered for sale until
the earliest of (i) the date upon which subscriptions for the Maximum Offering Amount offered hereunder have been accepted by
the Company, (ii) the date the Offering is terminated by the Company and (iii) September 30, 2018, subject to the right of the
Company and the Placement Agent to extend the Offering for an additional sixty (60) day period without prior notice to the investors
in the Offering (the “Termination Date”). The Placement Agent is acting in such capacity with respect
to the Offering on a “commercially reasonable best efforts” basis for the Maximum Offering Amount.

 

3.2
The Company may, in its discretion at any time
prior to the Termination Date, hold an initial closing (“Initial Closing”) and, at any time and from
time to time after the Initial Closing, may hold subsequent closings (each such closing, including the Initial Closing, a “Closing,”
and the final such Closing, the “Final Closing”), in each case, with respect to any Securities
for which subscriptions have been accepted prior to such date. In the event that (i) the Initial Closing does not occur prior
to the Termination Date or (ii) this Agreement or the aggregate Purchase Price owed with respect to the Securities purchased by
the Subscriber pursuant hereto is received after the Final Closing, all amounts paid by the Subscriber shall be returned to the
Subscriber, without interest or deduction. The Subscriber may revoke its subscription and obtain a return of the subscription
amount paid to the Escrow Account at any time before the date of the Initial Closing by providing written notice to the Placement
Agent, the Company and the Escrow Agent as provided in Section 6.1 below. Upon receipt of a revocation notice from the Subscriber
prior to the date of the Initial Closing, all amounts paid by the Subscriber shall be returned to the Subscriber, without interest
or deduction. The Subscriber may not revoke this subscription or obtain a return of the subscription amount paid to the Escrow
Agent on or after the date of the Initial Closing. Any subscription received after the Initial Closing but prior to the Termination
Date shall be irrevocable.

 

    	15

     

    

 

3.3
The minimum purchase that may be made by any
prospective investor shall be $50,000. Subscriptions for investment below the minimum investment may be accepted at the discretion
of the Placement Agent and the Company. The Company and the Placement Agent reserve the right to reject any subscription made
hereby, in whole or in part, in their sole discretion.

 

3.4
Prior to the applicable Closing for the Securities
purchased pursuant hereto, funds representing the aggregate Purchase Price for such Securities shall be deposited in the Escrow
Account.

 

3.5
Certificates representing the Preferred Stock
and the Warrants purchased by the Subscriber pursuant to this Agreement will be prepared for delivery to the Placement Agent for
further distribution to the Subscriber as soon as practicable following the applicable Closing. The Subscriber hereby authorizes
and directs the Company to deliver certificates representing the Securities purchased by the Subscriber pursuant to this Agreement
to the Placement Agent for further distribution directly to the Subscriber’s address indicated on the signature page hereto.

 

3.6
The Company’s agreement with each investor
in the Offering, including the Subscriber, is a separate agreement and the sale of the Securities to each investor in the Offering,
including the Subscriber, is a separate sale.

 

IV.
CONDITIONS TO OBLIGATIONS
OF THE SUBSCRIBER

 

4.1
The Subscriber’s obligation to purchase
the Securities at the Closing at which such purchase is to be consummated is subject to the fulfillment on or prior to such Closing
of the following conditions, which conditions may be waived at the option of the Subscriber to the extent permitted by law:

 

(a)
Representations and Warranties; Covenants.
The representations and warranties made by the Company in Section 2 shall be true and correct (without giving effect to any “Material
Adverse Effect,” “material,” “materially” or similar materiality qualifications therein, other than
Section 2.13(i)) in all material respects as of the date hereof and as of the Closing Date, except for those representations and
warranties which expressly relate to an earlier date, in which case such representations and warranties shall have been true and
correct in all material respects as of such earlier date (without giving effect to any “Material Adverse Effect”,
“material”, “materially” or other similar materiality qualification therein). All covenants, agreements
and conditions contained in this Agreement to be performed by the Company on or prior to the date of such Closing shall have been
performed or complied with in all material respects.

 

    	16

     

    

 

(b)
No Legal Order Pending. There shall not
then be in effect any legal or other order enjoining or restraining the transactions contemplated by this Agreement.

 

(c)
No Law Prohibiting or Restricting Such Sale.
There shall not be in effect any law, rule or regulation prohibiting or restricting such sale or requiring any consent or approval
of any person, which shall not have been obtained, to issue the Securities (except as otherwise provided in this Agreement).

 

(d)
No Suspensions of Trading in Common Stock;
Listing. Trading in the Common Stock shall not have been suspended by the SEC or any trading market (except for any suspensions
of trading of not more than one trading day solely to permit dissemination of material information regarding the Company) at any
time since the date of execution of this Agreement, and the Common Stock shall have been at all times since such date listed or
quoted for trading on the Company’s principal trading market.

 

(e)
Legal Opinion. The Company’s corporate
counsel shall have delivered a legal opinion addressed to Placement Agent in a form reasonably acceptable to the Placement Agent.

 

(f)
Notice of Disqualification Events. The
Company will notify the Subscribers and the Placement Agent in writing, prior to the Closing Date, of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to
become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.

 

V.
COVENANTS OF THE
COMPANY

 

5.1
Listing of Securities. The Company agrees,
(i) if the Company applies to have the Common Stock traded on any other trading market, it will include in such application the
Underlying Shares, and will take such other action as is necessary or desirable to cause the Underlying Shares to be listed on
such other trading market as promptly as possible, (ii) it will comply in all material respects with the Company’s reporting,
filing and other obligations under the Charter Documents or rules of the principal trading market of the Common Stock and (iii)
for so long as the Board of Directors determines that it remains advisable and in the Company’s best interest, the Company
will take all commercially reasonable action necessary to continue the listing and trading of its Common Stock on a trading market.

 

5.2
Reservation of Shares. The Company shall
at all times while the Preferred Stock and the Warrants are outstanding maintain a reserve from its duly authorized shares of
Common Stock of a number of shares of Common Stock sufficient to allow for the issuance of the Underlying Shares.

 

5.3
Replacement of Certificates. If any certificate
or instrument evidencing any Securities or the Underlying Shares is mutilated, lost, stolen or destroyed, the Company shall issue
or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft
or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement securities.
If a replacement certificate or instrument evidencing any securities is requested due to a mutilation thereof, the Company may
require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement.

 

    	17

     

    

 

5.4
Furnishing of Information.
Until no Subscriber owns any of the Securities, the Company covenants to maintain registration of the Common Stock under Section
12(g) or 12(b) of the Exchange Act and covenants to timely file (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. As long as Subscriber
owns Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to Subscriber
and make publicly available in accordance with Rule 144(c) such information as is required for the Subscribers to be able to sell
the Securities under Rule 144 within the requirements provided thereby. The Company further covenants that it will take such further
action as any holder of Securities may reasonably request, to the extent required from time to time, to enable such person to
sell such Securities without registration under the Securities Act within the requirements of the exemption provided by Rule 144.

 

5.5
Securities Laws; Publicity. The Company
shall file a Current Report on Form 8-K, including the Offering Materials as exhibits thereto (to the extent any information contained
therein is material, non-public information), with the SEC within the time required by the Exchange Act. From and after the filing
of such Current Report on Form 8-K the Company represents to the Subscriber (other than any Subscriber who has a representative
on the Company’s board of directors or who is an employee of the Company) that it shall have publicly disclosed all material,
non-public information delivered to any Subscriber by the Company or any of its Subsidiaries or any of its or their respective
officers, directors, employees or agents in connection with the transactions contemplated by the Offering Materials. In addition,
effective upon the filing of such Current Report on Form 8-K the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, agents, employees or Affiliates on the one hand, and the Subscriber or any of its Affiliates on
the other hand, shall terminate. The Company and the Placement Agent shall consult with each other in issuing any press releases
with respect to the transactions contemplated hereby. Notwithstanding the foregoing, the Company shall not publicly disclose the
name of any Subscriber, or include the name of any Subscriber in any filing with the SEC or any regulatory agency or trading market,
without the prior written consent of such Subscriber, except: (a) as required by federal securities law in connection with the
filing of any Offering Materials (including signature pages thereto) with the SEC and (b) to the extent such disclosure is otherwise
required by law, in which case the Company shall, if permitted by applicable law, provide the Subscriber with prior notice of
such disclosure permitted under this clause (b).

 

5.6
Form D; Blue Sky Filings. The Company
agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof promptly
upon request of the Subscriber. The Company shall take such action as the Company shall reasonably determine is necessary in order
to obtain an exemption for, or to qualify the Securities for, sale to the Subscriber at the Closing under applicable securities
or “blue sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request
of any Subscriber.

 

    	18

     

    

 

5.7
Equal Treatment of Subscribers. No consideration
(including any modification of any Offering Materials) shall be offered or paid to any person to amend or consent to a waiver
or modification of any provision of any of the Offering Materials unless the same consideration is also offered to all of the
investors in the Offering, including the Subscriber.

 

5.8
Non-Public Information. Except with respect
to the material terms and conditions of the transactions contemplated by the Offering Materials, the Company covenants and agrees
that neither it, nor any other person acting on its behalf, will provide Subscriber or its agents or counsel with any information
that the Company believes constitutes material non-public information, unless prior thereto Subscriber shall have executed a written
agreement regarding the confidentiality and use of such information. The Company understands and confirms that Subscriber shall
be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

5.9
Indemnification of Subscribers. Subject
to the provisions of this Section 5.9, the Company will indemnify and hold each Subscriber and its directors, officers, shareholders,
members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title), each Person who controls such Subscriber (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title) of such controlling persons (each, a “Subscriber Party”) harmless
from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable and documented attorneys’ fees and costs of investigation that any
such Subscriber Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties,
covenants or agreements made by the Company in this Agreement or in the other Offering Materials or (b) any action instituted
against the Subscriber Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company
who is not an Affiliate of such Subscriber Party, with respect to any of the transactions contemplated by the Offering Materials
(unless such action is based upon a breach of such Subscriber Party’s representations, warranties or covenants under the
Offering Materials or any agreements or understandings such Subscriber Party may have with any such stockholder or any violations
by such Subscriber Party of state or federal securities laws or any conduct by such Subscriber Party which constitutes fraud,
gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Subscriber Party in respect of
which indemnity may be sought pursuant to this Agreement, such Subscriber Party shall promptly, and in no event later than ten
(10) days after such Subscriber’s receipt of notice of such action, notify the Company in writing, and the Company shall
have the right to participate in or assume the defense thereof with counsel of its own choosing reasonably acceptable to the Subscriber
Party. Any Subscriber Party shall have the right to employ separate counsel in any such action and participate in the defense
thereof, but the fees and expenses of such counsel shall be at the expense of such Subscriber Party except to the extent that
(i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel,
a material conflict on any material issue between the position of the Company and the position of such Subscriber Party, in which
case the Company shall be responsible for the reasonable and documented fees and expenses of no more than one such separate counsel.
The Company will not be liable to any Subscriber Party under this Agreement (y) for any settlement by a Subscriber Party effected
without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to any Subscriber Party’s breach of any of
the representations, warranties, covenants or agreements made by such Subscriber Party in this Agreement or in the other Offering
Materials. The indemnification required by this Section 5.8 with respect to expenses shall be made by periodic payments of the
amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Subscriber Party against the Company
or others and any liabilities the Company may be subject to pursuant to law.

 

    	19

     

    

 

5.10
Use of Proceeds. The Company shall use
the net proceeds from the Offering for the purposes set forth in the Offering Materials.

 

5.11
Certificate of Designations. Prior to
the Initial Closing, the Company shall duly file the Certificate of Designation with the Secretary of State of the State of Delaware.

 

5.12
Registration Rights.

 

(a)
Piggy-Back Rights. If at any time on or after the six (6) month anniversary of the Final Closing, the Company proposes
to file a Registration Statement (as defined in Section 5.12(j)) under the Securities Act with respect to an offering of equity
securities, or securities or other obligations exercisable or exchangeable for, or convertible into, equity securities, by the
Company for its own account or for stockholders of the Company for their account (or by the Company and by stockholders of the
Company), other than a Registration Statement (i) filed in connection with any employee stock option or other benefit plan, (ii)
for an exchange offer or offering of securities solely to the Company’s existing stockholders, (iii) for an offering of
debt that is convertible into equity securities of the Company or (iv) for a dividend reinvestment plan, then the Company shall
(x) give written notice of such proposed filing to the holders of Registrable Securities (as defined in Section 5.12(j)) as soon
as practicable (but in no event less than ten (10) days) before the anticipated filing date, which notice shall describe the amount
and type of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing
Underwriter or Underwriters (as defined in Section 5.12(j)), if any, of the offering, and (y) offer to the holders of Registrable
Securities in such notice the opportunity to register the sale of such number of shares of Registrable Securities as such holder
may request in writing within five (5) days following receipt of such notice (a “Piggy-Back Registration”).
The Company shall cause such Registrable Securities to be included in such registration and shall use its best efforts to cause
the managing Underwriter or Underwriters of a proposed underwritten offering to permit the Registrable Securities requested to
be included in a Piggy-Back Registration on the same terms and conditions as any similar securities of the Company and to permit
the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof.
In the event a Piggy-Back Registration involves an Underwriter or Underwriters, all holders of Registrable Securities proposing
to distribute their securities through such Piggy-Back Registration shall enter into an underwriting agreement in customary form
with the Underwriter or Underwriters selected for such Piggy-Back Registration.

 

    	20

     

    

 

(b)
Reduction of Offering. If the managing Underwriter or Underwriters for a Piggy-Back Registration that is to be an underwritten
offering advises the Company and the holders of Registrable Securities proposing to distribute their securities through such Piggy-Back
Registration in writing that the dollar amount or number of shares of Common Stock which the Company desires to sell, taken together
with shares of Common Stock, if any, as to which registration has been demanded pursuant to written contractual arrangements with
persons other than the holders of Registrable Securities, the Registrable Securities as to which registration has been requested
under this Section 5.12, and the shares of Common Stock, if any, as to which registration has been requested pursuant to the written
contractual piggy-back registration rights of other stockholders of the Company, exceeds the maximum dollar amount or maximum
number of shares that can be sold in such offering without adversely affecting the proposed offering price, the timing, the distribution
method, or the probability of success of such offering (such maximum dollar amount or maximum number of shares, as applicable,
the “Maximum Number of Shares”), then the Company shall include in any such registration:

 

	 	(i)	If
    the registration is undertaken for the Company’s account: (A) first, the shares of Common Stock or other securities
    that the Company desires to sell that can be sold without exceeding the Maximum Number of Shares; (B) second, to the extent
    that the Maximum Number of Shares has not been reached under the foregoing clause (A), the shares of Common Stock as to which
    registration has been requested in the manner described in Section 5.12(a) of those certain Subscription Agreements that the
    Company entered into with the purchasers of shares of its Series E Convertible Preferred Stock dated April 16, 2018 or May
    17, 2018, as applicable (the “Series E Subscription Agreements”) that can be sold without exceeding
    the Maximum Number of Shares; (C) third, to the extent that the Maximum Number of Shares has not been reached under the foregoing
    clauses (A) and (B), the Registrable Securities as to which registration has been requested in the manner described in Section
    5.12(a) of this Agreement that can be sold without exceeding the Maximum Number of Shares (pro rata among participating holders
    of Registrable Securities based on the number of Registrable Securities requested to be included in such registration); and
    (D) fourth, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A), (B) and
    (C), the shares of Common Stock or other securities for the account of other persons that the Company is obligated to register
    pursuant to written contractual piggy-back registration rights with such persons and that can be sold without exceeding the
    Maximum Number of Shares; and
	 	 	 
	 	(ii)	If
    the registration is a “demand” registration undertaken at the demand of persons other than the holders of Registrable
    Securities, (A) first, the shares of Common Stock or other securities for the account of the demanding persons that can be
    sold without exceeding the Maximum Number of Shares; (B) second, to the extent that the Maximum Number of Shares has not been
    reached under the foregoing clause (A), the shares of Common Stock or other securities that the Company desires to sell that
    can be sold without exceeding the Maximum Number of Shares; (C) third, to the extent that the Maximum Number of Shares has
    not been reached under the foregoing clauses (A) and (B), the shares of Common Stock as to which registration has been requested
    pursuant to the terms of the Series E Subscription Agreements that can be sold without exceeding the Maximum Number of Shares;
    (D) fourth, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A), (B) and
    (C), the Registrable Securities as to which registration has been requested pursuant to the terms hereof that can be sold
    without exceeding the Maximum Number of Shares (pro rata among participating holders of Registrable Securities based on the
    number of Registrable Securities requested to be included in such registration); and (E) fifth, to the extent that the Maximum
    Number of Shares has not been reached under the foregoing clauses (A), (B) and (C), the shares of Common Stock or other securities
    for the account of other persons that the Company is obligated to register pursuant to written contractual arrangements with
    such persons, that can be sold without exceeding the Maximum Number of Shares.

 

    	21

     

    

 

(c)
Withdrawal. Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable
Securities in any Piggy-Back Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness
of the Registration Statement. The Company (whether on its own determination or as the result of a withdrawal by persons making
a demand pursuant to written contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness
of such Registration Statement. Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the holders
of Registrable Securities in connection with such Piggy-Back Registration as provided in Section 5.12(h).

 

(d)
Copies. The Company shall, prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto,
furnish, without charge, to the holders of Registrable Securities and such holders’ legal counsel copies of such Registration
Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits
thereto and documents incorporated by reference therein), the prospectus included in such Registration Statement (including each
preliminary prospectus), and such other documents as the holders of the Registrable Securities or legal counsel for any such holders
may request in order to facilitate the disposition of the Registrable Securities owned by such holders.

 

(e)
Amendments and Supplements. The Company shall prepare and file with the Commission such amendments, including post-effective
amendments, and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary
to keep such Registration Statement effective and in compliance with the provisions of the Securities Act until all Registrable
Securities and other securities covered by such Registration Statement have been disposed of in accordance with the intended method(s)
of distribution set forth in such Registration Statement or such securities have been withdrawn.

 

    	22

     

    

 

(f)
Notification. After the filing of a Registration Statement, the Company shall promptly, and in no event more than two (2)
business days after such filing, notify the holders of Registrable Securities included in such Registration Statement of such
filing, and shall further notify such holders promptly and confirm such advice in writing in all events within two (2) business
days of the occurrence of any of the following: (i) when such Registration Statement becomes effective; (ii) when any post-effective
amendment to such Registration Statement becomes effective; (iii) the issuance or threatened issuance by the Commission of any
stop order (and the Company shall take all actions required to prevent the entry of such stop order or to remove it if entered);
and (iv) any request by the Commission for any amendment or supplement to such Registration Statement or any prospectus relating
thereto or for additional information or of the occurrence of an event requiring the preparation of a supplement or amendment
to such prospectus so that, as thereafter delivered to the purchasers of the securities covered by such Registration Statement,
such prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading, and promptly make available to the holders of Registrable
Securities included in such Registration Statement any such supplement or amendment.

 

(g)
State Securities Laws Compliance. The Company shall use its best efforts to (i) register or qualify the Registrable Securities
covered by the Registration Statement under such securities or “blue sky” laws of such jurisdictions in the United
States as the holders of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution)
may request and (ii) take such action necessary to cause such Registrable Securities covered by the Registration Statement to
be registered with or approved by such other governmental authorities as may be necessary by virtue of the business and operations
of the Company and do any and all other acts and things that may be necessary or advisable to enable the holders of Registrable
Securities included in such Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions;
provided, however, that the Company shall not be required to qualify generally to do business in any jurisdiction
where it would not otherwise be required to qualify but for this paragraph or subject itself to taxation in any such jurisdiction.

 

(h)
Registration Expenses. The Company shall bear all costs and expenses incurred in connection with any Piggy-Back Registration,
whether or not the Registration Statement becomes effective. The Holders shall have no obligation to pay any underwriting discounts
or selling commissions or bear any expenses of the underwriters in connection with any Piggy-Back Registration.

 

(i)
Information. The holders of Registrable Securities included in any Registration Statement shall provide such information
as may reasonably be requested by the Company, or the managing Underwriter, if any, in connection with the preparation of such
Registration Statement, including amendments and supplements thereto, in order to effect the registration of any Registrable Securities
under the Securities Act pursuant to Section 5.12(a).

 

    	23

     

    

 

(j)
Definitions. For purposes of this Section 5.12, unless the context requires otherwise, the following terms shall have the
meanings indicated below:

 

“Registrable
Securities” means all of the Underlying Shares issuable from time to time to all of the Subscribers in the Offering.
Registrable Securities also include any warrants, shares of capital stock or other securities of the Company issued as a dividend
or other distribution with respect to or in exchange for or in replacement of such Underlying Shares. As to any particular Registrable
Securities, such securities shall cease to be Registrable Securities when: (a) a Registration Statement with respect to the sale
of such securities shall have become effective under the Securities Act and such securities shall have been sold, transferred,
disposed of or exchanged in accordance with such Registration Statement; (b) such securities shall have been otherwise transferred,
new certificates for them not bearing a legend restricting further transfer shall have been delivered by the Company and subsequent
public distribution of them shall not require registration under the Securities Act; (c) such securities shall have ceased to
be outstanding; or (d) the Registrable Securities are freely saleable under Rule 144 without volume limitations.

 

“Registration
Statement” means a registration statement filed by the Company with the SEC in compliance with the Securities Act
and the rules and regulations promulgated thereunder for a public offering and sale of equity securities, or securities or other
obligations exercisable or exchangeable for, or convertible into, equity securities (other than a registration statement on Form
S-4 or Form S-8, or their successors, or any registration statement covering only securities proposed to be issued in exchange
for securities or assets of another entity).

 

“Underwriter”
means a securities dealer who purchases any Registrable Securities as principal in an underwritten offering and not as part of
such dealer’s market-making activities.

 

VI.
MISCELLANEOUS

 

6.1
Any notice or other communication given hereunder
shall be deemed sufficient if in writing and sent by registered or certified mail, return receipt requested, delivered by hand
against written receipt therefor, or sent in portable document format (“pdf) via electronic mail, addressed as follows:

 

if
to the Company, to it at:

 

Adhera
Therapeutics, Inc.

4721 Emperor Boulevard, Suite 350

Durham, North Carolina 27703

Attn: Robert C. Moscato, Jr.,

Chief
Executive Officer

Email: rmoscato@adherathera.com

With
a copy to (which shall not constitute notice):

 

Pryor
Cashman LLP

7 Times Square

New York, New York 10036

Attn: Lawrence Remmel, Esq.

Email: lremmel@pryorcashman.com

 

    	24

     

    

 

if
to the Subscriber, to the Subscriber’s address indicated on the signature page of this Agreement.

 

With
a copy to (which shall not constitute notice):

 

Attn:

Email:

 

if
to the Escrow Agent, to it at:

 

Corporate
Stock Transfer

3200 Cherry Creek Drive, South

Suite 430

Denver, CO 80209

Attn: Carylyn Ball, President

Email: cbell@corporatestock.com

 

With
a copy to (which shall not constitute notice):

 

Collegiate
Peaks Bank

885 S. Colorado Blvd

Denver, CO 80246

Attn: Hope Spencer

Email: hope.spencergcollegiatepeaksbank.com

 

6.2
Notices shall be deemed to have been given or
delivered (i) on the third (3rd) business day following the date of postmark in the case of delivery by registered or certified
mail, (ii) on the date of delivery in the case of delivery by hand or (iii) on the date of delivery if delivered by electronic
mail; provided that if such e-mail is received after 4:00 p.m. Eastern Time on a business day or at any time on a non-business
day, such notice shall be deemed delivered on the following business day. Except as otherwise provided herein, this Agreement
shall not be changed, modified or amended except by a writing signed by the Company and the Subscriber, and this Agreement may
not be discharged except by performance in accordance with its terms or by a writing signed by the Company and the Subscriber.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

6.3
This Agreement shall be binding upon and inure
to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights
or obligations hereunder without the prior written consent of each Subscriber (other than in connection with a change of control
or by operation of law). Any Subscriber may assign any or all of its rights under this Agreement to any Person to whom such Subscriber
assigns or transfers any Securities or Registrable Securities (including the rights set forth in Section 5.12 of this Agreement),
provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of
the Offering Materials that apply to the “Subscribers.”

 

    	25

     

    

 

6.4
The Offering Materials, together with the exhibits
hereto and thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all
prior agreements and understandings, oral or written, with respect to such matters. The Placement Agent shall be deemed a third
party beneficiary of the representations and warranties and covenants made by the Company and the Subscriber in this Agreement.

 

6.5
Upon the execution and delivery of this Agreement
by the Subscriber and the Company, this Agreement shall become a binding obligation of the Subscriber with respect to the purchase
of Securities as provided herein; provided, however, that, for the avoidance of doubt, the Company hereby reserves the right to
(i) enter into subscription agreements with other prospective investors in the Offering and (ii) reject any subscription, in whole
or in part, including, as applicable, that of the Subscriber, provided the Company returns to such prospective investor any funds
paid by such prospective investor(s), with respect to such rejected subscription or portion thereof, without interest or deduction.

 

6.6
Any action, arbitration, claim, hearing, litigation
or suit (whether civil, criminal, administrative, judicial or investigative, whether formal or informal, whether public or private)
commenced, brought, conducted or heard by or before any federal, state, local or foreign government or any court of competent
jurisdiction, administrative or regulatory body, agency, bureau, or commission in any domestic or foreign jurisdiction, any appropriate
division of any of the foregoing or any arbitrator, or other legal action (each, a “Proceeding”) relating to this
Agreement or the transactions contemplated hereby shall be governed by and construed and enforced in accordance with the internal
laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all Proceedings
concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Offering
Materials (whether brought against a party hereto or its affiliates, directors, officers, shareholders, employees or agents) shall
be commenced exclusively in the state and federal courts sitting in the Southern District of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the Southern District of New York for the adjudication
of any Proceeding related to this Agreement, the other Offering Materials or the transactions contemplated hereby or thereby,
and hereby irrevocably waives, and agrees not to assert in any Proceeding that it is not personally subject to the jurisdiction
of any such court, that Proceeding is improper or is an inconvenient venue for such Proceeding.

 

6.7
In order to discourage frivolous Proceedings
the parties agree that unless a claimant in any Proceeding arising out of this Agreement succeeds in establishing a claim and
recovering a judgment against another party (regardless of whether such claimant succeeds against one of the other parties to
the Proceeding), then the non-claimant party shall be entitled to recover from such claimant all of such other party’s reasonable
legal costs and expenses relating to such Proceeding and/or incurred in preparation therefor.

 

6.8
If any provision of this Agreement, or the application
of such provision to any person or circumstance, shall be held invalid by a court of competent jurisdiction, the remainder of
this Agreement, or the application of such provision to persons or circumstances other than those to which it is held invalid
by such court, shall not be affected thereby.

 

    	26

     

    

 

6.9
Subject to applicable statute of limitations,
the representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

 

6.10
The Company and the Subscriber agree to execute
and deliver all such further documents, agreements and instruments and take such other and further action as may be necessary
or appropriate to carry out the purposes and intent of this Agreement.

 

6.11
This Agreement may be executed in any number
of counterparts, each of which shall be deemed to be an original, but such counterparts together shall constitute one and the
same instrument. Delivery of executed signature pages hereof by facsimile transmission or pdf shall constitute effective and binding
execution and delivery of this Agreement.

 

6.12
Nothing in this Agreement shall create or be
deemed to create any rights or remedies in any person or entity that is not a party to this Agreement.

 

6.13
The Company and the Subscriber agree that in
the event of any breach or threatened breach by the other party of any covenant, obligation or other provision set forth in this
Agreement, the non-breaching or non-threatening party, as applicable, shall be entitled (in addition to any other remedy that
may be available to it) to seek (a) a decree or order of specific performance or mandamus to enforce the observance and performance
of such covenant, obligation or other provision, and (b) an injunction restraining such breach or threatened breach.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    	27

     

    

 

APPENDIX B 

 

	SHARES
    OF PREFERRED STOCK BEING SUBSCRIBED FOR:________________
	 
	PURCHASE
    PRICE (PER SHARE): $____________
	 
	AGGREGATE
    PURCHASE PRICE: ____________________

 

 

	 	 	 
	Signature	 	Signature
    (if purchasing jointly)
	 	 	 
	 	 	 
	Name
    Typed or Printed	 	Name
    Typed or Printed
	 	 	 
	 	 	 
	Title
    (if Subscriber is an Entity)	 	Title
    (if Subscriber is an Entity)
	 	 	 
	 	 	 
	Address	 	Address
	 	 	 
	 	 	 
	City,
    State and Zip Code	 	City,
    State and Zip Code
	 	 	 
	 	 	 
	Telephone-Business	 	Telephone-Business
	 	 	 
	 	 	 
	Telephone-Residence	 	Telephone-Residence
	 	 	 
	 	 	 
	Tax
    ID # or Social Security #	 	Tax
    ID # or Social Security #
	 	 	 
	 	 	 
	E-Mail
    Address	 	E-Mail
    Address

 

Name
in which Securities should be issued:

 

Dated:
                    ,
2018

 

    	28

     

    

 

This
Subscription Agreement is agreed to and accepted as of __________, 2018.

 

ADHERA
THERAPEUTICS, INC.

 

	By:
    	 	 
	Name:	Robert
    C. Moscato, Jr.	 
	Title	Chief
    Executive OfficerExhibit
10.35 

 

ADHERA
THERAPEUTICS, INC.

 

2018
LONG-TERM INCENTIVE PLAN

 

*
* * * *

 

1.
Purpose. The purpose of the Adhera Therapeutics, Inc. 2018 Long-Term Incentive Plan (the “Plan”)
is to further and promote the interests of Adhera Therapeutics, Inc. (the “Company”), its Subsidiaries and
its stockholders by enabling the Company and its Subsidiaries to attract, retain and motivate employees, directors and consultants,
or those who will become employees, directors or consultants, and to align the interests of those individuals and the Company’s
stockholders. To do this, the Plan offers performance-based incentive awards and equity-based opportunities providing such employees,
directors and consultants with a proprietary interest in maximizing the growth, profitability and overall success of the Company
and its Subsidiaries.

 

2.
Definitions. For purposes of the Plan, the following terms shall have the meanings set forth below:

 

2.1
“Award” means an award or grant made to a Participant under Sections 6, 7, 8 and/or 9 of the Plan.

 

2.2
“Award Agreement” means the agreement executed by a Participant pursuant to Sections 3.2 and 15.7 of the Plan
in connection with the granting of an Award.

 

2.3
“Board” means the Board of Directors of the Company, as constituted from time to time.

 

2.4
“Code” means the Internal Revenue Code of 1986, as in effect and as amended from time to time, or any successor
statute thereto, together with any rules, regulations and interpretations promulgated thereunder or with respect thereto.

 

2.5
“Committee” means the committee of the Board established to administer the Plan, as described in Section 3 of
the Plan, or if no such committee has been appointed or established, the Board.

 

2.6
“Common Stock” means the Common Stock, par value $0.006 per share, of the Company, or any security of the Company
issued by the Company in substitution or exchange therefor.

 

    	 	1	 

     

    

 

2.7
“Company” means Adhera Therapeutics, Inc., a Delaware corporation, or any successor entity to Adhera Therapeutics,
Inc.

 

2.8
“Exchange Act” means the Securities Exchange Act of 1934, as in effect and as amended from time to time, or any
successor statute thereto, together with any rules, regulations and interpretations promulgated thereunder or with respect thereto.

 

2.9
“Fair Market Value” means on, or with respect to, any given date(s), the average of the highest and lowest market
prices of the Common Stock, as reported on a public exchange for such date(s) or, if the Common Stock was not traded on such date(s),
on the next preceding day or days on which the Common Stock was traded. If at any time the Common Stock is not traded on an exchange,
the Fair Market Value of a share of the Common Stock shall be determined in good faith by the Board.

 

2.10
“Incentive Stock Option” means any stock option granted pursuant to the provisions of Section 6 of the Plan (and
the relevant Award Agreement) that is intended to be (and is specifically designated as) an “incentive stock option”
within the meaning of Section 422 of the Code.

 

2.11
“Non-Qualified Stock Option” means any stock option granted pursuant to the provisions of Section 6 of the Plan
(and the relevant Award Agreement) that is not (and is specifically designated as not being) an Incentive Stock Option.

 

2.12
“Participant” means any individual who is selected from time to time under Section 5 to receive an Award under
the Plan.

 

2.13
“Performance Units” means the monetary units granted under Section 9 of the Plan and the relevant Award Agreement.

 

2.14
“Plan” means the Adhera Therapeutics, Inc. 2018 Long-Term Incentive Plan, as set forth herein and as in effect
and as amended from time to time (together with any rules and regulations promulgated by the Committee with respect thereto).

 

2.15
“Restricted Shares” means the restricted shares of Common Stock granted pursuant to the provisions of Section
8 of the Plan and the relevant Award Agreement.

 

2.16
“Stock Appreciation Right” means an Award described in Section 7.2 of the Plan and granted pursuant to the provisions
of Section 7 of the Plan.

 

2.17
“Subsidiary(ies)” means any corporation (other than the Company), trust, partnership or limited liability company
in an unbroken chain of entities, including and beginning with the Company, if each of such entities, other than the last entity
in the unbroken chain, owns, directly or indirectly, more than fifty percent (50%) of the voting shares, partnership, beneficial
or membership interests in one of the other entities in such chain.

 

    	 	2	 

     

    

 

3.
Administration.

 

3.1
The Committee. The Plan shall be administered by the Committee. Subject to the last sentence of this Section 3.1, the
Committee shall be appointed from time to time by the Board and shall be comprised of not less than two (2) of the then members
of the Board who are Non-Employee Directors (within the meaning of SEC Rule 16b-3(b)(3)) of the Company. Consistent with the Bylaws
of the Company, members of the Committee shall serve at the pleasure of the Board and the Board, subject to the immediately preceding
sentence, may at any time and from time to time remove members from, or add members to, the Committee. In the event that the Board
has not appointed the Committee, then the Board shall have all the powers of the Committee under the Plan.

 

3.2
Plan Administration and Plan Rules. The Committee is authorized to construe and interpret the Plan and to promulgate,
amend and rescind rules and regulations relating to the implementation, administration and maintenance of the Plan. Subject to
the terms and conditions of the Plan, the Committee shall make all determinations necessary or advisable for the implementation,
administration and maintenance of the Plan including, without limitation, (a) selecting the Plan’s Participants, (b) making
Awards in such amounts and form as the Committee shall determine, (c) imposing such restrictions, terms and conditions upon such
Awards as the Committee shall deem appropriate, and (d) correcting any technical defect(s) or technical omission(s), or reconciling
any technical inconsistency(ies), in the Plan and/or any Award Agreement. The Committee may designate persons other than members
of the Committee to carry out the day-to-day ministerial administration of the Plan under such conditions and limitations as it
may prescribe, except that the Committee shall not delegate its authority with regard to the selection for participation in the
Plan and/or the granting of any Awards to Participants. The Committee’s determinations under the Plan need not be uniform
and may be made selectively among Participants, whether or not such Participants are similarly situated. Any determination, decision
or action of the Committee in connection with the construction, interpretation, administration, implementation or maintenance
of the Plan shall be final, conclusive and binding upon all Participants and any person(s) claiming under or through any Participants.
The Company shall effect the granting of Awards under the Plan, in accordance with the determinations made by the Committee, by
execution of written agreements and/or other instruments in such form as is approved by the Committee. The Committee may, in its
sole discretion, delegate its authority to one or more senior executive officers for the purpose of making Awards to Participants
who are not subject to Section 16 of the Exchange Act.

 

3.3
Liability Limitation. Neither the Board nor the Committee, nor any member of either, shall be liable for any act, omission,
interpretation, construction or determination made in good faith in connection with the Plan (or any Award Agreement), and the
members of the Board and the Committee shall be entitled to indemnification and reimbursement by the Company in respect of any
claim, loss, damage or expense (including, without limitation, attorneys’ fees) arising or resulting therefrom to the fullest
extent permitted by law and/or under any directors and officers liability insurance coverage which may be in effect from time
to time.

 

    	 	3	 

     

    

 

4.
Term of Plan/Common Stock Subject to Plan.

 

4.1
Term. Unless terminated earlier by the Board, the Plan shall terminate on July 10, 2028, except with respect to Awards
then outstanding. After such date no further Awards shall be granted under the Plan.

 

4.2
Common Stock. The maximum number of shares of Common Stock in respect of which Awards may be granted or paid out under
the Plan, subject to adjustment as provided in Section 13.2 of the Plan, shall not exceed six million (6,000,000) shares; all
of which may be issued pursuant to the exercise of Incentive Stock Options. In the event of a change in the Common Stock of the
Company that is limited to a change in the designation thereof to “Capital Stock” or other similar designation, or
to a change in the par value thereof, or from par value to no par value, without increase or decrease in the number of issued
shares, the shares resulting from any such change shall be deemed to be the Common Stock for purposes of the Plan. Common Stock
which may be issued under the Plan may be either authorized and unissued shares or issued shares which have been reacquired by
the Company (in the open-market or in private transactions) and which are being held as treasury shares. No fractional shares
of Common Stock shall be issued under the Plan.

 

4.3
Computation of Available Shares. For the purpose of computing the total number of shares of Common Stock available
for Awards under the Plan, there shall be counted against the limitations set forth in Section 4.2 of the Plan the maximum number
of shares of Common Stock potentially subject to issuance upon exercise or settlement of Awards granted under Sections 6 and 7
of the Plan, the number of shares of Common Stock issued under grants of Restricted Shares pursuant to Section 8 of the Plan and
the maximum number of shares of Common Stock potentially issuable under grants or payments of Performance Units pursuant to Section
9 of the Plan, in each case determined as of the date on which such Awards are granted. If any Awards expire unexercised or are
forfeited, surrendered, cancelled, terminated or settled in cash in lieu of Common Stock, the shares of Common Stock which were
theretofore subject (or potentially subject) to such Awards shall again be available for Awards under the Plan to the extent of
such expiration, forfeiture, surrender, cancellation, termination or settlement of such Awards.

 

5.
Eligibility. Individuals eligible for Awards under the Plan shall consist of employees, directors and consultants,
or those who will become employees, directors or consultants, of the Company and/or its Subsidiaries whose performance or contribution,
in the sole discretion of the Committee, benefits or will benefit the Company or any Subsidiary.

 

6.
Stock Options.

 

6.1
Terms and Conditions. Stock options granted under the Plan shall be in respect of Common Stock and may be in the form
of Incentive Stock Options or Non-Qualified Stock Options (sometimes referred to collectively herein as the “Stock Option(s)”).
Such Stock Options shall be subject to the terms and conditions set forth in this Section 6 and any additional terms and conditions,
not inconsistent with the express terms and provisions of the Plan, as the Committee shall set forth in the relevant Award Agreement.

 

    	 	4	 

     

    

 

6.2
Grant. Stock Options may be granted under the Plan in such form as the Committee may from time to time approve. Stock
Options may be granted alone or in addition to other Awards under the Plan or in tandem with Stock Appreciation Rights. Special
provisions shall apply to Incentive Stock Options granted to any employee who owns (within the meaning of Section 422(b)(6) of
the Code) more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or its parent
corporation or any subsidiary of the Company, within the meaning of Sections 424(e) and (f) of the Code (a “10% Shareholder”).

 

6.3
Exercise Price. The exercise price per share of Common Stock subject to a Stock Option shall be determined by the Committee;
provided, however, that the exercise price of a Stock Option shall not be less than one hundred percent (100%) of
the Fair Market Value of the Common Stock on the date of the grant of such Stock Option; provided, further, however,
that, in the case of a 10% Shareholder, the exercise price of an Incentive Stock Option shall not be less than one hundred ten
percent (110%) of the Fair Market Value of the Common Stock on the date of grant.

 

6.4
Term. The term of each Stock Option shall be such period of time as is fixed by the Committee; provided, however,
that the term of any Incentive Stock Option shall not exceed ten (10) years (five (5) years, in the case of a 10% Shareholder)
after the date immediately preceding the date on which the Incentive Stock Option is granted.

 

6.5
Method of Exercise. A Stock Option may be exercised, in whole or in part, by giving written notice of exercise to the
Secretary of the Company, or the Secretary’s designee, specifying the number of shares to be purchased. Such notice shall
be accompanied by payment in full of the exercise price (and applicable tax withholding) in cash, by certified check, bank draft,
or money order payable to the order of the Company, or, if permitted by the Committee in its sole discretion, by delivery of shares
of Common Stock satisfying such requirements as the Committee shall establish, or through such other mechanism as the Committee
shall permit, in its sole discretion. Payment instruments shall be received by the Company subject to collection. The proceeds
received by the Company upon exercise of any Stock Option may be used by the Company for general corporate purposes. Any portion
of a Stock Option that is exercised may not be exercised again.

 

6.6
Tandem Grants. If Non-Qualified Stock Options and Stock Appreciation Rights are granted in tandem, as designated in
the relevant Award Agreements, the right of a Participant to exercise any such tandem Stock Option shall terminate to the extent
that the shares of Common Stock subject to such Stock Option are used to calculate amounts or shares receivable upon the exercise
of the related tandem Stock Appreciation Right.

 

7.
Stock Appreciation Rights.

 

7.1
Terms and Conditions. The grant of Stock Appreciation Rights under the Plan shall be subject to the terms and conditions
set forth in this Section 7 and any additional terms and conditions, not inconsistent with the express terms and provisions of
the Plan, as the Committee shall set forth in the relevant Award Agreement.

 

    	 	5	 

     

    

 

7.2
Stock Appreciation Rights. A Stock Appreciation Right is an Award granted with respect to a specified number of shares
of Common Stock entitling a Participant to receive an amount equal to the excess of the Fair Market Value of a share of Common
Stock on the date of exercise over the Fair Market Value of a share of Common Stock on the date of grant of the Stock Appreciation
Right, multiplied by the number of shares of Common Stock with respect to which the Stock Appreciation Right shall have been exercised.

 

7.3
Grant. A Stock Appreciation Right may be granted in addition to any other Award under the Plan or in tandem with or
independent of a Non-Qualified Stock Option.

 

7.4
Date of Exercisability. In respect of any Stock Appreciation Right granted under the Plan, unless otherwise (a) determined
by the Committee (in its sole discretion) at any time and from time to time in respect of any such Stock Appreciation Right, or
(b) provided in the Award Agreement, a Stock Appreciation Right may be exercised by a Participant, in accordance with and subject
to all of the procedures established by the Committee, in whole or in part at any time and from time to time during its specified
term. The Committee may also provide, as set forth in the relevant Award Agreement and without limitation, that some Stock Appreciation
Rights shall be automatically exercised and settled on one or more fixed dates specified therein by the Committee.

 

7.5
Form of Payment. Upon exercise of a Stock Appreciation Right, payment may be made in cash, in Restricted Shares or
in shares of unrestricted Common Stock, or in any combination thereof, as the Committee, in its sole discretion, shall determine
and provide in the relevant Award Agreement.

 

7.6
Tandem Grant. The right of a Participant to exercise a tandem Stock Appreciation Right shall terminate to the extent
such Participant exercises the Non-Qualified Stock Option to which such Stock Appreciation Right is related.

 

8.
Restricted Shares.

 

8.1
Terms and Conditions. Grants of Restricted Shares shall be subject to the terms and conditions set forth in this Section
8 and any additional terms and conditions, not inconsistent with the express terms and provisions of the Plan, as the Committee
shall set forth in the relevant Award Agreement. Restricted Shares may be granted alone or in addition to any other Awards under
the Plan. Subject to the terms of the Plan, the Committee shall determine the number of Restricted Shares to be granted to a Participant
and the Committee may provide or impose different terms and conditions on any particular Restricted Share grant made to any Participant.
With respect to each Participant receiving an Award of Restricted Shares, there shall be issued a stock certificate (or certificates)
in respect of such Restricted Shares. Such stock certificate(s) shall be registered in the name of such Participant, shall be
accompanied by a stock power duly executed by such Participant, and shall bear, among other required legends, the following legend:

 

    	 	6	 

     

    

 

“The
transferability of this certificate and the shares of stock represented hereby are subject to the terms and conditions (including,
without limitation, forfeiture events) contained in the Adhera Therapeutics, Inc. 2018 Long-Term Incentive Plan and an Award Agreement
entered into between the registered owner hereof and Adhera Therapeutics, Inc. Copies of such Plan and Award Agreement are on
file in the office of the Secretary of Adhera Therapeutics, Inc. Adhera Therapeutics, Inc. will furnish to the recordholder of
the certificate, without charge and upon written request at its principal place of business, a copy of such Plan and Award Agreement.
Adhera Therapeutics, Inc. reserves the right to refuse to record the transfer of this certificate until all such restrictions
are satisfied, all such terms are complied with and all such conditions are satisfied.”

 

Such
stock certificate evidencing such shares shall, in the sole discretion of the Committee, be deposited with and held in custody
by the Company until the restrictions thereon shall have lapsed and all of the terms and conditions applicable to such grant shall
have been satisfied.

 

8.2
Restricted Share Grants. A grant of Restricted Shares is an Award of shares of Common Stock granted to a Participant,
subject to such restrictions, terms and conditions as the Committee deems appropriate, including, without limitation, (a) restrictions
on the sale, assignment, transfer, hypothecation or other disposition of such shares, (b) the requirement that the Participant
deposit such shares with the Company while such shares are subject to such restrictions, and (c) the requirement that such shares
be forfeited upon termination of employment for specified reasons within a specified period of time or for other reasons (including,
without limitation, the failure to achieve designated performance goals).

 

8.3
Restriction Period. In accordance with Sections 8.1 and 8.2 of the Plan and unless otherwise determined by the Committee
(in its sole discretion) at any time and from time to time, Restricted Shares shall only become unrestricted and vested in the
Participant in accordance with such vesting schedule relating to such Restricted Shares, if any, as the Committee may establish
in the relevant Award Agreement (the “Restriction Period”). During the Restriction Period, such stock shall
be and remain unvested and a Participant may not sell, assign, transfer, pledge, encumber or otherwise dispose of or hypothecate
such Award. Upon satisfaction of the vesting schedule and any other applicable restrictions, terms and conditions, the Participant
shall be entitled to receive payment of the Restricted Shares or a portion thereof, as the case may be, as provided in Section
8.4 of the Plan.

 

8.4
Payment of Restricted Share Grants. After the satisfaction and/or lapse of the restrictions, terms and conditions established
by the Committee in respect of a grant of Restricted Shares, a new certificate, without the legend set forth in Section 8.1 of
the Plan, for the number of shares of Common Stock which are no longer subject to such restrictions, terms and conditions shall,
as soon as practicable thereafter, be delivered to the Participant, provided that the removal of such legend is permitted by applicable
federal and state securities laws.

 

    	 	7	 

     

    

 

8.5
Shareholder Rights. A Participant shall have, with respect to the shares of Common Stock underlying a grant of Restricted
Shares, all of the rights of a shareholder of such stock (except as such rights are limited or restricted under the Plan or in
the relevant Award Agreement). Any stock dividends paid in respect of unvested Restricted Shares shall be treated as additional
Restricted Shares and shall be subject to the same restrictions and other terms and conditions that apply to the unvested Restricted
Shares in respect of which such stock dividends are issued.

 

9.
Performance Units.

 

9.1
Terms and Conditions. Performance Units shall be subject to the terms and conditions set forth in this Section 9 and
any additional terms and conditions, not inconsistent with the express provisions of the Plan, as the Committee shall set forth
in the relevant Award Agreement.

 

9.2
Performance Unit Grants. A Performance Unit is an Award of units (with each unit representing such monetary amount
as is designated by the Committee in the Award Agreement) granted to a Participant, subject to such terms and conditions as the
Committee deems appropriate, including, without limitation, the requirement that the Participant forfeit such units (or a portion
thereof) in the event certain performance criteria or other conditions are not met within a designated period of time.

 

9.3
Grants. Performance Units may be granted alone or in addition to any other Awards under the Plan. Subject to the terms
of the Plan, the Committee shall determine the number of Performance Units to be granted to a Participant and the Committee may
impose different terms and conditions on any particular Performance Units granted to any Participant.

 

9.4
Performance Goals and Performance Periods. Participants receiving a grant of Performance Units shall only earn into
and be entitled to payment in respect of such Awards if the Company and/or the Participant achieves certain performance goals
(the “Performance Goals”) during and in respect of a designated performance period (the “Performance
Period”). The Performance Goals and the Performance Period shall be established by the Committee, in its sole discretion.
The Committee shall establish Performance Goals for each Performance Period prior to, or as soon as practicable after, the commencement
of such Performance Period. The Committee shall also establish a schedule or schedules for Performance Units setting forth the
portion of the Award which will be earned or forfeited based on the degree of achievement, or lack thereof, of the Performance
Goals at the end of the relevant Performance Period. In setting Performance Goals, the Committee may use, but shall not be limited
to, such measures as total shareholder return, return on equity, net earnings growth, sales or revenue growth, cash flow, comparisons
to peer companies, individual or aggregate Participant performance or such other measure or measures of performance as the Committee,
in its sole discretion, may deem appropriate. Such performance measures shall be defined as to their respective components and
meaning by the Committee (in its sole discretion). During any Performance Period, the Committee shall have the authority to adjust
the Performance Goals and/or the Performance Period in such manner as the Committee, in its sole discretion, deems appropriate
at any time and from time to time.

 

    	 	8	 

     

    

 

9.5
Payment of Units. With respect to each Performance Unit, the Participant shall, if the applicable Performance Goals
have been achieved, or partially achieved, as determined by the Committee in its sole discretion, by the Company and/or the Participant
during the relevant Performance Period, be entitled to receive payment in an amount equal to the designated value of each Performance
Unit times the number of such units so earned. Payment in settlement of earned Performance Units shall be made as soon as practicable
following the conclusion of the respective Performance Period in cash, in unrestricted Common Stock, or in Restricted Shares,
or in any combination thereof, as the Committee, in its sole discretion, shall determine and provide in the relevant Award Agreement.

 

10.
Other Provisions.

 

10.1
Performance-Based Awards. Performance Units, Restricted Shares, and other Awards subject to performance criteria shall
be paid solely on account of the attainment of one or more pre-established performance goals. Until otherwise determined by the
Committee, the performance goals shall be the attainment of pre-established levels of any of net income, market price per share,
earnings per share, return on equity, return on capital employed and/or cash flow, regulatory approval of products, strategic
alliances and joint ventures and patent issuances.

 

11.
Dividend Equivalents. In addition to the provisions of Section 8.5 of the Plan, Awards of Stock Options, and/or Stock
Appreciation Rights, may, in the sole discretion of the Committee and if provided for in the relevant Award Agreement, earn dividend
equivalents. In respect of any such Award which is outstanding on a dividend record date for Common Stock, the Participant shall
be credited with an amount equal to the amount of cash or stock dividends that would have been paid on the shares of Common Stock
covered by such Award had such covered shares been issued and outstanding on such dividend record date. The Committee shall establish
such rules and procedures governing the crediting of such dividend equivalents, including, without limitation, the amount, timing,
form of payment and payment contingencies and/or restrictions of such dividend equivalents, as it deems appropriate or necessary.

 

12.
Non-transferability of Awards. Unless otherwise provided in the Award Agreement, no Award under the Plan or any Award
Agreement, and no rights or interests herein or therein, shall or may be assigned, transferred, sold, exchanged, encumbered, pledged,
or otherwise hypothecated or disposed of by a Participant or any beneficiary(ies) of any Participant, except by testamentary disposition
by the Participant or the laws of intestate succession. No such interest shall be subject to execution, attachment or similar
legal process, including, without limitation, seizure for the payment of the Participant’s debts, judgments, alimony, or
separate maintenance. Unless otherwise provided in the Award Agreement, during the lifetime of a Participant, Stock Options and
Stock Appreciation Rights are exercisable only by the Participant.

 

13.
Changes in Capitalization and Other Matters.

 

13.1
No Corporate Action Restriction. The existence of the Plan, any Award Agreement and/or the Awards granted hereunder
shall not limit, affect or restrict in any way the right or power of the Board or the stockholders of the Company to make or authorize
(a) any adjustment, recapitalization, reorganization or other change in the Company’s or any Subsidiary’s capital
structure or its business, (b) any merger, consolidation or change in the ownership of the Company or any Subsidiary, (c) any
issue of bonds, debentures, capital, preferred or prior preference stocks ahead of or affecting the Company’s or any Subsidiary’s
capital stock or the rights thereof, (d) any dissolution or liquidation of the Company or any Subsidiary, (e) any sale or transfer
of all or any part of the Company’s or any Subsidiary’s assets or business, or (f) any other corporate act or proceeding
by the Company or any Subsidiary. No Participant, beneficiary or any other person shall have any claim against any member of the
Board or the Committee, the Company or any Subsidiary, or any employees, officers, shareholders or agents of the Company or any
subsidiary, as a result of any such action.

 

    	 	9	 

     

    

 

13.2
Recapitalization Adjustments. In the event that the Board determines that any dividend or other distribution (whether
in the form of cash, Common Stock, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization,
merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Common Stock or other securities of the Company,
or other corporate transaction or event affects the Common Stock such that an adjustment is determined by the Board, in its sole
discretion, to be necessary or appropriate in order to prevent dilution or enlargement of benefits or potential benefits intended
to be made available under the Plan, the Board may, in such manner as it in good faith deems equitable, adjust any or all of (i)
the number of shares of Common Stock or other securities of the Company (or number and kind of other securities or property) with
respect to which Awards may be granted, (ii) the number of shares of Common Stock or other securities of the Company (or number
and kind of other securities or property) subject to outstanding Awards, and (iii) the exercise price with respect to any Stock
Option, or make provision for an immediate cash payment to the holder of an outstanding Award in consideration for the cancellation
of such Award.

 

13.3
Mergers. If the Company enters into or is involved in any merger, reorganization, recapitalization, sale of all or
substantially all of the Company’s assets, liquidation, or business combination with any person or entity (such merger,
reorganization, recapitalization, sale of all or substantially all of the Company’s assets, liquidation, or business combination
to be referred to herein as a “Merger Event”), the Board may take such action as it deems appropriate, including,
but not limited to, replacing such Stock Options with substitute stock options and/or stock appreciation rights in respect of
the shares, other securities or other property of the surviving corporation or any affiliate of the surviving corporation on such
terms and conditions, as to the number of shares, pricing and otherwise, which shall substantially preserve the value, rights
and benefits of any affected Stock Options or Stock Appreciation Rights granted hereunder as of the date of the consummation of
the Merger Event. Notwithstanding anything to the contrary in the Plan, if any Merger Event occurs, the Company shall have the
right, but not the obligation, to cancel each Participant’s Stock Options and/or Stock Appreciation Rights and to pay to
each affected Participant in connection with the cancellation of such Participant’s Stock Options and/or Stock Appreciation
Rights, an amount equal to the excess of the Fair Market Value, as determined by the Board, of the Common Stock underlying any
unexercised Stock Options or Stock Appreciation Rights (whether then exercisable or not) over the aggregate exercise price of
such unexercised Stock Options and/or Stock Appreciation Rights.

 

Upon
receipt by any affected Participant of any such substitute stock options, stock appreciation rights (or payment) as a result of
any such Merger Event, such Participant’s affected Stock Options and/or Stock Appreciation Rights for which such substitute
options and/or stock appreciation rights (or payment) were received shall be thereupon cancelled without the need for obtaining
the consent of any such affected Participant.

 

    	 	10	 

     

    

 

14.
Amendment, Suspension and Termination.

 

14.1
In General. The Board may suspend or terminate the Plan (or any portion thereof) at any time and may amend the Plan
at any time and from time to time in such respects as the Board may deem advisable to insure that any and all Awards conform to
or otherwise reflect any change in applicable laws or regulations, or to permit the Company or the Participants to benefit from
any change in applicable laws or regulations, or in any other respect the Board may deem to be in the best interests of the Company
or any Subsidiary. No such amendment, suspension or termination shall (x) materially adversely affect the rights of any Participant
under any outstanding Stock Options, Stock Appreciation Rights, Performance Units, or Restricted Share grants, without the consent
of such Participant, or (y) increase the number of shares available for Awards pursuant to Section 4.2 or change the performance
criteria listed in Section 10.1, without shareholder approval; provided, however, that the Board may amend the Plan,
without the consent of any Participants, in any way it deems appropriate to satisfy Code Section 409A and any regulations or other
authority promulgated thereunder, including any amendment to the Plan to cause certain Awards not to be subject to Code Section
409A.

 

14.2
Award Agreement Modifications. The Committee may (in its sole discretion) amend or modify at any time and from time
to time the terms and provisions of any outstanding Stock Options, Stock Appreciation Rights, Performance Units, or Restricted
Share grants, in any manner to the extent that the Committee under the Plan or any Award Agreement could have initially determined
the restrictions, terms and provisions of such Stock Options, Stock Appreciation Rights, Performance Units, and/or Restricted
Share grants, including, without limitation, changing or accelerating (a) the date or dates as of which such Stock Options or
Stock Appreciation Rights shall become exercisable, (b) the date or dates as of which such Restricted Share grants shall become
vested, or (c) the performance period or goals in respect of any Performance Units. No such amendment or modification shall, however,
materially adversely affect the rights of any Participant under any such Award without the consent of such Participant; provided,
however, that the Committee may amend an Award without the consent of the Participant, in any way it deems appropriate to satisfy
Code Section 409A and any regulations or other authority promulgated thereunder, including any amendment to or modification of
such Award to cause such Award not to be subject to Code Section 409A.

 

15.
Miscellaneous.

 

15.1
Tax Withholding. The Company shall have the right to deduct from any payment or settlement under the Plan, including,
without limitation, the exercise of any Stock Option or Stock Appreciation Right, or the delivery, transfer or vesting of any
Common Stock or Restricted Shares, any federal, state, local or other taxes of any kind which the Committee, in its sole discretion,
deems necessary to be withheld to comply with the Code and/or any other applicable law, rule or regulation. Shares of Common Stock
may be used to satisfy any such tax withholding. Such Common Stock shall be valued based on the Fair Market Value of such stock
as of the date the tax withholding is required to be made, such date to be determined by the Committee. In addition, the Company
shall have the right to require payment from a Participant to cover any applicable withholding or other employment taxes due upon
any payment or settlement under the Plan.

 

    	 	11	 

     

    

 

15.2
No Right to Employment. Neither the adoption of the Plan, the granting of any Award, nor the execution of any Award
Agreement, shall confer upon any employee of the Company or any Subsidiary any right to continued employment with the Company
or any Subsidiary, as the case may be, nor shall it interfere in any way with the right, if any, of the Company or any Subsidiary
to terminate the employment of any employee at any time for any reason.

 

15.3
Unfunded Plan. The Plan shall be unfunded and the Company shall not be required to segregate any assets in connection
with any Awards under the Plan. Any liability of the Company to any person with respect to any Award under the Plan or any Award
Agreement shall be based solely upon the contractual obligations that may be created as a result of the Plan or any such award
or agreement. No such obligation of the Company shall be deemed to be secured by any pledge of, encumbrance on, or other interest
in, any property or asset of the Company or any Subsidiary. Nothing contained in the Plan or any Award Agreement shall be construed
as creating in respect of any Participant (or beneficiary thereof or any other person) any equity or other interest of any kind
in any assets of the Company or any Subsidiary or creating a trust of any kind or a fiduciary relationship of any kind between
the Company, any Subsidiary and/or any such Participant, any beneficiary thereof or any other person.

 

15.4
Payments to a Trust. The Committee is authorized to cause to be established a trust agreement or several trust agreements
or similar arrangements from which the Committee may make payments of amounts due or to become due to any Participants under the
Plan.

 

15.5
Other Company Benefit and Compensation Programs. Payments and other benefits received by a Participant under an Award
made pursuant to the Plan shall not be deemed a part of a Participant’s compensation for purposes of the determination of
benefits under any other employee welfare or benefit plans or arrangements, if any, provided by the Company or any Subsidiary
unless expressly provided in such other plans or arrangements, or except where the Board expressly determines in writing that
inclusion of an Award or portion of an Award should be included to accurately reflect competitive compensation practices or to
recognize that an Award has been made in lieu of a portion of competitive annual base salary or other cash compensation. Awards
under the Plan may be made in addition to, in combination with, or as alternatives to, grants, awards or payments under any other
plans or arrangements of the Company or its Subsidiaries. The existence of the Plan notwithstanding, the Company or any Subsidiary
may adopt such other compensation plans or programs and additional compensation arrangements as it deems necessary to attract,
retain and motivate employees.

 

    	 	12	 

     

    

 

15.6
Listing, Registration and Other Legal Compliance. No Awards or shares of the Common Stock shall be required to be issued
or granted under the Plan unless legal counsel for the Company shall be satisfied that such issuance or grant will be in compliance
with all applicable federal and state securities laws and regulations and any other applicable laws or regulations. The Committee
may require, as a condition of any payment or share issuance, that certain agreements, undertakings, representations, certificates,
and/or information, as the Committee may deem necessary or advisable, be executed or provided to the Company to assure compliance
with all such applicable laws or regulations. Certificates for shares of the Restricted Shares and/or Common Stock delivered under
the Plan may be subject to such stock-transfer orders and such other restrictions as the Committee may deem advisable under the
rules, regulations, or other requirements of the Securities and Exchange Commission, any stock exchange upon which the Common
Stock is then listed, and any applicable federal or state securities law. In addition, if, at any time specified herein (or in
any Award Agreement or otherwise) for (a) the making of any Award, or the making of any determination, (b) the issuance or other
distribution of Restricted Shares and/or Common Stock, or (c) the payment of amounts to or through a Participant with respect
to any Award, any law, rule, regulation or other requirement of any governmental authority or agency shall require either the
Company, any Subsidiary or any Participant (or any estate, designated beneficiary or other legal representative thereof) to take
any action in connection with any such determination, any such shares to be issued or distributed, any such payment, or the making
of any such determination, as the case may be, shall be deferred until such required action is taken. With respect to persons
subject to Section 16 of the Exchange Act, transactions under the Plan are intended to comply with all applicable conditions of
Rule 16b-3 promulgated under the Exchange Act.

 

15.7 Award
Agreements. Each Participant receiving an Award under the Plan shall enter into an Award Agreement with the Company
in a form specified by the Committee. Each such Participant shall agree to the restrictions, terms and conditions of the
Award set forth therein and in the Plan.

 

15.8
Designation of Beneficiary. Each Participant to whom an Award has been made under the Plan may designate a beneficiary
or beneficiaries to exercise any option or to receive any payment which under the terms of the Plan and the relevant Award Agreement
may become exercisable or payable on or after the Participant’s death. At any time, and from time to time, any such designation
may be changed or cancelled by the Participant without the consent of any such beneficiary. Any such designation, change or cancellation
must be on a form provided for that purpose by the Committee and shall not be effective until received by the Committee. If no
beneficiary has been designated by a deceased Participant, or if the designated beneficiaries have predeceased the Participant,
the beneficiary shall be the Participant’s estate. If the Participant designates more than one beneficiary, any payments
under the Plan to such beneficiaries shall be made in equal shares unless the Participant has expressly designated otherwise,
in which case the payments shall be made in the shares designated by the Participant.

 

15.9
Leaves of Absence/Transfers. The Committee shall have the power to promulgate rules and regulations and to make determinations,
as it deems appropriate, under the Plan in respect of any leave of absence from the Company or any Subsidiary granted to a Participant.
Without limiting the generality of the foregoing, the Committee may determine whether any such leave of absence shall be treated
as if the Participant has terminated employment with the Company or any such Subsidiary. If a Participant transfers within the
Company, or to or from any Subsidiary, such Participant shall not be deemed to have terminated employment as a result of such
transfers.

 

    	 	13	 

     

    

 

15.10
Code Section 409A. This Plan and all Awards hereunder are intended to comply with the requirements of Code Section
409A and any regulations or other authority promulgated thereunder. Notwithstanding any provision of the Plan or any Award Agreement
to the contrary, the Board and the Committee reserve the right (without the consent of any Participant and without any obligation
to do so or to indemnify any Participant or the beneficiaries of any Participant for any failure to do so) to amend this Plan
and/or any Award Agreement as and when necessary or desirable to conform to or otherwise properly reflect any guidance issued
under Code Section 409A after the date hereof without violating Code Section 409A. In the event that any payment or benefit made
hereunder would constitute payments or benefits pursuant to a non-qualified deferred compensation plan within the meaning of Code
Section 409A and, at the time of a Participant’s “separation from service”, such Participant is a “specified
employee” within the meaning of Code Section 409A, then any such payments or benefits shall be delayed until the six-month
anniversary of the date of such Participant’s “separation from service”. Each payment made under this Plan shall
be designated as a “separate payment” within the meaning of Code Section 409A.

 

15.11
Governing Law. The Plan and all actions taken thereunder shall be governed by and construed in accordance with the
laws of the State of Delaware, without reference to the principles of conflict of laws thereof. Any titles and headings herein
are for reference purposes only, and shall in no way limit, define or otherwise affect the meaning, construction or interpretation
of any provisions of the Plan.

 

15.12
Effective Date. The Plan shall be effective upon its approval by the Board and adoption by the Company, subject to
the approval of the Plan by the Company’s stockholders in accordance with Section 422 of the Code.

 

[remainder
of page intentionally left blank]

 

    	 	14	 

     

    

 

IN
WITNESS WHEREOF, this Plan is adopted by the Company on this 10th day of July, 2018.

 

	 	ADHERA
    THERAPEUTICS, INC. 
	 	 	 
	 	By:	/s/
    Robert C. Moscato, Jr.
	 	Name:	Robert
    C. Moscato, Jr.
	 	Title:	Chief
    Executive Officer

 

    	 	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]